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ABSTRACT 
UNIVERSITY OF SUSSEX 
 
 
STEPHEN PETER GARNETT RUSHTON 
DOCTOR OF PHILOSOPHY 
 
NOVEL ROUTES TO KAINOIDS: 
 THE TOTAL SYNTHESIS OF (-)-α-KAINIC ACID 
 
 
 This thesis contains three chapters concerning synthetic studies towards the alkaloids   
(-)-α-kainic acid; a natural product isolated from the Japanese marine algae Kainin-sou               
(海人草) or Digenea simplex and the close family member (-)-domoic acid isolated from 
another Japanese marine algae Doumoi or Chondria armata. 
 
 Chapter one gives an introduction to the isolation, structure and biological activity of 
kainic acid, domoic acid and their analogues. Chapter one also contains a discussion of the 
previous syntheses of both kainic acid, domoic acid and domoic acid C. It is written with the 
aim of selecting key aspects of each synthesis and in turn gives a critical account of each piece 
of work. Chapter two is concerned with the results obtained from the experimental section of 
this thesis. Disclosed is a novel method for the construction of (-)-α-kainic acid via an ene-
reaction on a 1,6-diene intermediate. The synthesis comprises of eight linear steps from readily 
available D-serine and through the use of simple methodology forms the target compound 
kainic acid in a satisfactory overall yield of 20 %. This thesis also investigates the possibility of 
installing a variety of side chains to the biologically active kainoid core via a cross-metathesis 
reaction on an unsaturated carbon appendage. Chapter three contains the experimental 
procedures carried out for the synthesis of the compounds discussed in chapter two. 
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CHAPTER 1: Introduction 
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1.1 The Kainoid Amino Acid Family 
1.1.1 Background 
 The kainoid amino acids are an exclusive group of non-proteinogenic pyrrolidine 
dicarboxylic acids. They all have 3 asymmetric centres at positions 2, 3 and 4 of the pyrrolidine 
ring with the relative configurations; S, S and S or R respectively. Variations on the C-4 
substituent where some degree of unsaturation is retained provide access to the different 
kainoids (Figure 1.1)
1
. 
 
 Kainoid amino acids are well known for their insecticidal and anthelmintic
2
 properties. 
More importantly these excitatory amino acids (EAAs) are known for their neuroexcitatory 
activity in the mammalian central nervous system where they act as analogues of the excitatory 
amino acid L-glutamate (L-Glu)
3
. These biological properties have been well investigated with 
respect to neurodegenerative disorders such as Alzheimer’s4,5, Huntington’s chorea6,7 and 
epilepsy
8
.
 
Today it is the interest in these properties that provides the driving force for these 
compounds as targets of asymmetric synthesis. 
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Figure 1.1: Kainoid Amino Acids1 
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1.2 (-)-(α)-Kainic Acid (1.1), (-)-Domoic Acid (1.3) and Iso-domoic Acid 
C (1.6) 
1.2.1 Background, Structure and Isolation 
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Figure 1.2: (-)-(α)-Kainic Acid (1.1), (-)-Domoic Acid (1.3) and Iso-Domoic Acid C (1.6) 
 
 The inhabitants of Japan have utilised the ability of kainoids to expel helminths or 
parasitic worms from the body for over a thousand years. Residents on Yakushima Island, just 
off the south eastern tip of mainland Japan, discovered that an extract of algae acted as  a 
powerful insecticide
9
. The observation of these potent biological properties led to the first 
isolation of the parent member; (-)-α-kainic acid (1.1) or digenic acid, from extraction of the 
Japanese marine algae Kainin-sou (海人草) or Digenea simplex in 195310. Kainic acid (1.1) has 
since been found in the algae Centrocerus clavulatum
11
 and the Corsican moss Alsidium 
helminthocorton
12,13
.   
 
 Structure elucidation via degradation studies carried out by Japanese groups in the 
1950’s14-16, (a seminal example being soda-lime distillation which led to the isolation of a 
pyrrole) supported by X-ray experiments revealed the relative stereochemistry, however 
assignment of absolute stereochemistry remained elusive until Oppolzer and Thirring reported 
the total synthesis in 1982
17
. The carboxylate at the C-2 carbon and the alkyl carboxylate at the 
C-3 centre are each joined to the pyrrole ring through chiral carbons of S stereochemical 
configuration. In (-)-(α)-kainic acid the stereochemical configuration of the C-4 centre is also S. 
One example that demonstrates the importance of the stereochemistry in this molecule is an 
epimer of (-)-(α)-kainic acid which has an R configuration at the C-4 centre. This compound is 
called (+)-(α)-allokainic acid (1.2) (Figure 1.1) and has markedly reduced biological activity 
when compared to kainic acid(1.1)
18
.   
 
 (-)-Domoic acid (1.3) contains an octadienic side chain at the C-4 carbon and was 
originally isolated from another Japanese marine algae Doumoi or Chondria armata in 1958
19
. 
Since then it has also been extracted from Canadian phytoplankton Pseudo-nitzschia multiseries 
 16 
 
(formally Nitzschia pungens f)
20
 and many other species of Pseudo-nitzschia following human 
poisoning from contaminated shellfish on Prince Edward Island in 1987
21
. The initially 
proposed trans-trans configuration of the alkene and unknown stereochemistry at C-5 carbon,  
were redefined as cis-trans with an absolute stereochemistry of R at the C-5 carbon following 
the total synthesis from Ohfune and Tomita also in 1982
22
. 
 
Iso-domoic acid C (1.6) is one isomer of many analogous to domoic acid (1.3). All of 
the iso-domoic acids contain the kainate core, can be isolated from both Nitzschia pungens and 
Chondria armata and exhibit insecticidal properties
9
 although many including iso-domoic acid 
C (1.6) show markedly reduced activity when compared to domoic acid (1.3)
23,24
. 
 
1.2.2 Biological Activity 
Kainates administered intravenously cause selective neuronal degeneration analogous to 
that seen in sufferers of  Huntington’s chorea25. Thus kainates have been used as tools in 
experimental models for Huntington’s chorea6,7 and other central nervous system disorders such 
as
 
epilepsy
8
, and senile dementia
26-29
. Due to their high neurotoxity in mammals, kainoids 
themselves are unlikely ever to become part of a treatment for such neuronal diseases. Despite 
this, the valuable information gained from experimental models has provided further 
identification of receptor subtypes and their distribution, which could lead to new solutions in 
the treatment of neuronal diseases for the future. 
 
 Kainates follow the same mode of action as L-Glutumate (L-Glu) after its release from 
glutamatergic nerve terminals. Both travel across the post-synaptic cleft to bind with their 
respective membrane bound receptors (GluRs)
30
. These EAA receptors are further sub-divided 
into the ionotropic receptors (iGluRs) which act as ligand-gated ion channels and regulate the 
movement of K
+
, Na
+
, and Ca
2+
 cations. Kainates act as agonists on the KA receptor subtype 
and on binding cause a confirmational change which allows an influx of cations into the post-
synaptic cleft. These receptors play a key role in many fundamental processes including 
neuronal development, learning and memory, but cell death can occur due to overstimulation
30
.  
 
 As with many of the kainoid amino acids’ biological properties, the neuroexcitatory 
activity has been shown to be strongly dependent on the C-4 substituent
18,31,32
. CPAA (1.17), 
which has no C-4 appendage, shows no selectivity at kainate-type receptors (Figure 1.3)
31
. The 
orientation
18
, -nature32 and conformation31 of the C-4 substituent are all important factors in 
giving kainoids their excitatory activity. The cis-relationship existing between the C-3 and C-4 
substituent’s gives kainic acid (1.1) enhanced excitatory activity when compared to the C-4 
 17 
 
epimer allokainic acid (1.2)
18
. -Bond functionality has also been shown to be essential for 
neuroexcitatory activity
32
. Dihydrokainic acid (1.18), which has no -electrons within its C-4 
substituent, exhibits no excitatory activity (Figure 1.3) 
31
.  
 
N
H
CO2H
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N
H
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Figure 1.3: CPAA (1.17) and Dihydrokainic Acid (1.18) 
 
1.2.3 Biosynthesis 
 An investigation into the biosynthesis of (-)-domoic acid (1.3) was undertaken by 
Wright et al.
33
. Labelling studies revealed evidence of condensation of a glutamic acid 
derivative (1.20) with a geranyl pyrophosphate (1.19) with subsequent cyclisation to form a 
proline ring (Scheme 1.1). A similar biosynthetic pathway was suggested for (-)-α-kainic acid 
(1.1) involving isopentenyl pyrophosphate instead of (1.19). Separate experiments with [1-
13
C]acetate and [1,2-
13
C]acetate feedstocks and a N. pungens culture revealed a biosynthetic 
pathway whereby both biogenetic units are entirely derived from acetate
33
. Analysis of the 
labelling patterns from hyperfine splitting on 
13
C-NMR spectra confirmed that the proline ring 
is derived from combination of a geranyl unit and an activated citric acid cycle intermediate. 
Further analysis of labelling patterns gave evidence that the geranyl portion of this molecule 
was of isoprenoid origin. 
 
PPO
H
H2N CO2H
CO2H
LG
N
H
CO2H
CO2H
HO2C
(-)-domoic acid (1.3)(1.19) (1.20)  
Scheme 1.1: Biosynthetic Pathway to Domoic Acid (1.3) 
 
1.2.4 Previous Syntheses of (-)-(α)-Kainic Acid (1.1) 
 The non-trivial formation of the highly functionalised pyrrolidine ring containing three 
contiguous asymmetric centres has attracted significant synthetic interest, particularly with 
regard to the crucial syn-relationship that exists between the substituents at the C-3 and C-4 
 18 
 
positions. Many past syntheses have solved this issue through a stereoselective formation of the 
C-3/C-4 bond or by controlling a stereoselective ring closure with the C-2 substituent. There 
have been more than 30 enantioselective syntheses and numerous racemic investigations 
covering a wide variety of strategies to the kainoid core (many of which are included in reviews 
by Parsons
1
 and Moloney
30
). Despite this devotion placing kainic acid (1.1) as one of the most 
investigated synthetic targets to date. All syntheses are limited in yield, stereoselectivity and 
scale.  
 
 The following is by no means intended to provide a comprehensive review. The 
included examples have been chosen either as representatives of a particular synthetic approach, 
because they are relevant to this project or they have been completed within the last 5 years. 
 
 Oppolzer and Thirring described the first enantioselective synthesis of kainic acid (1.1) 
in 1982 (Scheme 1.2)
17
. Comprising of only six steps, this remains one of the simplest and 
shortest syntheses to date. The 1,6-diene intermediate (1.22) prepared from (S)-(+)-5-glutamate 
(1.21) was used stereoselectively to form the C-3/C-4 bond in kainic acid (1.1). This bond was 
formed by an intramolecular ene-reaction under the direction of the C-2 unit and afforded the 
pyrrolidine (1.23). Removal of the protecting groups and oxidation of the alcohol to the acid, 
gave kainic acid (1.1) in a respectable 5% overall yield. 
 
EtO2C
NHBoc
CO2H
(1.21)
N
Boc OTBS
(1.22)
N
Boc OTBS
CO2Et
(1.23)
CO2Et
 
Reagents and Conditions: i. 5% solution in toluene, 130˚C, 40h (70%). 
Scheme 1.2: Oppolzer and Thirring’s Route17 
 
 The use of the ene-reaction to construct the kainoid skeleton was further developed by 
Yoo in 1990
34
 (Scheme 1.3). Yoo utilised a palladium(0) catalysed formal ene-reaction or 
palladium(0) mediated olefin insertion-carbonylation reaction from a functionalised vinyl allylic 
acetate (1.25) to provide a mixture of the pyrrolidine ring systems found in kainoids (1.26, 
1.27). The C-2 substituent controls the stereochemistry at C-3 but not C-4. It took an extra 5 
steps to complete the synthesis of kainic acid (1.1). 
 
 
 i) 
 19 
 
  
Reagents and Conditions: i. , ii. PhCOCl. iii. Pd(dba)2 (7%), PPh3 (15%), CO (3 atm), 80˚C in 
acetic acid followed by hydrolysis and esterification (25% and 35% respectively). 
Scheme 1.3 Yoo’s 1st Route34 
 
 Ogasawara’s first synthesis of kainic acid (1.1) in 1997 also highlights the usefulness of 
intramolecular ene-reactions for construction of the kainoid core (Scheme 1.4)
35
. Precursors 
(1.28 +1.29) were formed from (±)-ketodicyclopentadiene and underwent a concurrent retro-
Diels-Alder reaction and a synchronous, stereospecific ene-reaction of the transient 1,6-diene 
(1.30), to afford the all cis-product (1.31) in good yield and >99% ee. The bicyclic pyrrolidine 
(1.31) provided the skeletal structure to access kainic acid (1.1). 
 
NCbz
CO2Me
CbzN CO2Me
CbzN CO2Me
N
Cbz
MeO2C
+
(1.28)
(1.29)
(1.30)
(1.31)
                                 
Reagents and Conditions: i. Ph2O, reflux, (80%, >99ee). 
Scheme 1.4: Ogasawara’s 1st Route35 
 
 Ogasawara published a second synthesis of kainic acid (1.1) in 2000 involving a one-
pot Chugaev syn-elimination and ene-reaction as the key step (Scheme 1.5)
36
. The xanthate 
ester (1.32) was obtained from enantiopure (+)-cis-4-carbobenzoxyamino-2-cyclopentenol. 
AcO
Cl
  i), ii) iii) 
iii) 
 20 
 
Thermolysis of the xanthate (1.32) provided a single diastereomer of pyrrolidine (1.34). The 
authors suggest that the all cis-stereochemistry would be consistent with the formation of a 
transient exo-1,6-diene (1.33). Acid hydrolysis, cleavage and oxidation resulted in a diester, 
which underwent epimerisation of the C-2 position to give the correct configuration for ()-
kainic acid (1.1). 
 
NCbz
O
O
OCS2Me
O
O
NCbz
H
"exo"
NCbz O
O
(1.32) (1.33) (1.34)
 
Reagents and Conditions: i. NaHCO3, Ph2O, reflux (72%). 
Scheme 1.5: Ogasawara’s 2nd Route36 
 
 In 2000 Ganem utilised a metal-mediated enantioselective ene-reaction of the achiral 
diene (1.35) (Scheme 1.6)
37
. Bis-oxazoline ligand (1.39) directed high diastereoselectivity 
favouring pyrrolidine (1.36), however formation of the nitrile (1.38) failed to give the expected 
trans-selectivity. Further hydrolysis of both the ester and the nitrile groups, followed by base-
promoted epimerisation of the C-2 substituent afforded ()-kainic acid (1.1) in a good overall 
yield of 20%. 
N
O
N
O
Ph Ph
N
COPh
CO2Et
O
N
COPh
CO2Et
CN
(1.39)
(1.35) (1.37)
(1.38)
N
COPh
CO2Et
O N
COPh
CO2Et
O
(1.36)
 
Reagents and Conditions: i. (1.39), Mg(ClO4)2, CH2Cl2 (72%, (1.36:1.37) (>20:1)); ii. Cp2ZrHCl, THF. 
iii. TMSCN, CH2Cl2 (70% over 2 steps). 
Scheme 1.6: Ganem’s Route37 
 
i) 
i) 
ii, iii) 
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Chalker presented two, more syntheses in 2007
38
 that highlight chemistry first 
pioneered by Oppolzer for creating cis-substituted heterocycles through the use of a palladium-
catalysed zinc-ene cyclisation of allyl acetates
39
. Chalker applied this strategy to both an allyl 
phenyl sulfone (1.40) and allyl chloride (1.41) to provide the cis-substituted pyrrolidine 
precursor (1.42) that was readily converted to ()-kainic acid (1.1) (Scheme 1.7). 
 
N
Bn
N
Bn
OTBS
PhO2S
Cl N
Bn
OTBS
OTBS
I
"single
diastereomer "
(1.40)
(1.41)
(1.42)
 
Reagents and Conditions: i.1) Pd
(0)
, ZnEt2 2) I2 (55%); ii.1) Pd
(0)
, ZnEt2 2) I2 (91%). 
Scheme 1.7: Chalker’s Routes38 
 
 The most recent use of the ene-reaction has been in a neat synthesis from Tilve at the 
university of Goa in 2009 (Scheme 1.8)
40
. In this instance, he shows how a tandem Wittig-ene 
reaction can be used to install the desirable cis-C-3/C-4 stereocentres of kainic acid (1.1). 
Phosphorane (1.43) was prepared and upon refluxing with aqueous glyoxalic acid in toluene, 
pyrrolidone (1.44) was formed. This could then be deprotected and esterified in one reaction 
with ceric ammonium nitrate (CAN) and then re-esterifiied to Ganem’s advanced intermediate 
(1.45)
37
 without affecting the cis-stereochemistry. 
 
N
PMB
PPh3
O N
PMB
O
CO2H
N
H
O
CO2Et
(1.43) (1.44) (1.45)  
Reagents and Conditions: i. 50% aq. CHOCO2H, toluene, 110°C, 24h, (60% (20:1 cis:trans)). 
Scheme 1.8: Tilve’s Route40 
 
 Knight communicated in 1987 that a stereocontrolled Ireland-Claisen rearrangement 
could be employed to construct kainic acid’s (1.1) core structure (Scheme 1.9)41,42. Precursor 
i) 
ii) 
i) 
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(1.46) was formed from L-aspartic acid and the enolate Claisen rearrangement gave exclusively 
the tri-substituted pyrrolidine (1.47) in a 55% yield following hydrolysis of the silyl ester. 
Arndt-Eistert homologation of the acid (1.47) gave the methyl ester (1.48), which was easily 
converted to kainic acid (1.1). 
O
N
O
OTIPS
CO2Et
N
CO2Et
CO2H
OTIPS
N
CO2Et
OTIPS
CO2Me
(1.46) (1.47) (1.48)  
Reagents and Conditions: i. LDA, TBSCl, THF, -100 to 20ºC; ii. K2CO3, MeOH/H2O (55% over 2 steps). 
Scheme 1.9: Knight’s Route41 
 
 In 1988 Takano uncovered an intramolecular Diels-Alder reaction of heterodiene (1.50)  
which, could be used to construct the cis-C-3/C-4 ring junction of kainic acid (1.1) (Scheme 
1.10)
43
. The heterodiene (1.50), formed from a Knoevengal condensation of glyceraldehyde 
(1.49) with Meldrum’s acid, participated in a spontaneous intramolecular [4+2]-cycloaddition to 
give (1.51) as a single diastereomer. The stereocontrol was theorised to be a result of the sp
2
-
planar-like configuration of the carbamate nitrogen, which allows efficient [4π+2π]-overlap of 
only the endo-conformer. The formation and subsequent opening of lactone (1.51) provided a 
suitable precursor to be taken on to kainic acid (1.1). 
(1.49) (1.50)
(1.51)
N
Cbz
O
OBn N
Cbz OBn
O
O
O
O
N
Cbz OBn
O O
O
OHH
 
Reagents and Conditions: i. Meldrum’s Acid, EDDA. 
Scheme 1.10: Takano’s Route43 
 
i, ii) 
i) 
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 In 1990 Baldwin showed the C-3/C-4 bond in kainic acid (1.1) could be constructed via 
a cobalt mediated radical cyclisation of an appropriately modified D-serine precursor (1.52) 
(Scheme 1.11)
44
. This method gave an inseparable mixture of the desired compound (1.53) and 
an α,β-unsaturated ester (1.54) Treatment with base, protection of the resultant amine and re-
esterification, gave both C-4 isomers (1.55 + 1.56) in a 45% and 11% yield respectively. 
Baldwin observed that the constrained oxazolidinyl moiety enhanced C-3/C-4 stereocontrol 
during ring closure when compared to the previous approach involving the open chain iodide 
(1.57) (Scheme 1.12)
45,46
. The pyrrolidine (1.55) yielded kainic acid (1.1) in a further four steps. 
 
N
O
O
CO2tBuI
N
O
O
N
O
O
CO2tBu
(1.52) (1.53) (1.54)
N
OH
CO2Me
Boc
(1.55)
+
N
OH
CO2Me
Boc
(1.56)
CO2tBu
(45%) (11%)
 
Reagents and Conditions: i. Co
(I)
, MeOH (51%, (1.44:1.45) (4:1)); ii. NaOH, dioxane, 70ºC then (Boc)2O 
iii. CH2N2, MeOH. 
Scheme 1.11: Baldwin’s 1st Route44 
 
+
N
I OBn
OTBS
CO2Ph
N
OH
OBn
CO2Ph
(1.57) (1.58)
(50%) (30%)
N
OH
OBn
CO2Ph
(1.59)
 
Reagents and Conditions: i. Co
(I)
, MeOH. 
Scheme 1.12: Baldwin’s  Open Chain Iodide Route45,46 
 
 In 1994 Yoo employed a rigid oxazolidinone moiety (1.60) in a Pauson-Khand reaction 
under standard conditions to provide exclusively the single diastereomer (1.61) in 93% yield 
i) 
ii, iii) 
i) 
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(Scheme 1.13)
47
, thereby improving on his synthesis published a year earlier
48
. This again 
shows the usefulness of constraining the conformation of these molecules when seeking to 
install the cis-ring juncture of kainic acid (1.1). After further extensive manipulations involving 
formation of a lactone ring and subsequent reductive cleavage of the lactone, kainic acid (1.1) 
was finally obtained. 
N
O
O
(1.60) (1.61)
O
N
O
O
 
Reagents and Conditions: i. Co2(CO)8, CH2Cl2. ii. TMANO (93% over 2 steps). 
Scheme 1.13: Yoo’s 3rd Route47 
 
 Hanessian published a synthesis of kainic acid (1.1) in 1996 which, proceeded via a 
trimethyl stannyl mediated radical carbocyclisation of an oxazolidinyl diene (1.62) (Scheme 
1.14)
49
. This stereochemically controlled cyclisation provided predominately the bicycle (1.63), 
but also its inseparable C-4 epimer (1.64) in 88% yield and in a ratio of 2.8:1 respectively. The 
carbon-tin bond was then cleaved by CAN in methanol to give dimethyl acetals (1.65 + 1.66) in 
36% and 14% yield respectively. Following careful elaboration to avoid any epimerisation of 
the C-4 centre, acetal (1.65) gave kainic acid (1.1). 
 
 
 
i, ii) 
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(1.62) (1.63)
tBuO2C
N
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O
CO2tBu
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MeO
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O
CO2tBu
OMe
MeO
(1.65) (1.66)
(38%) (14%)
N
O
O
CO2tBuMe3Sn
(1.64)
 
Reagents and Conditions: i. Me3SnCl, NaCNBH3, 
t
BuOH, AIBN, Δ (88%, (1.63:1.64) (2.8:1)); ii. CAN, 
MeOH, rt. 
Scheme 1.14: Hanessian’s Route49 
 
 In 1999 Montgomery highlighted a novel synthesis of kainic acid (1.1) which utilised a 
nickel mediated cyclisation of allene precursor (1.67) (Scheme 1.15)
50
. Interestingly the allene 
component of precursor (1.67) was installed following chemistry developed by Crabbé
51-53
 for 
the homologation of an alkyne. Treatment of (1.67) with dimethylzinc in presence of biscod 
nickel and titanium isopropoxide directly afforded the bicyclic compound (1.71) in a reasonable 
yield of 57% and with a fortuitous diastereomeric ratio of 97:3 in favour of kainic acid’s (1.1) 
stereochemistry. 
 
i) 
ii) 
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X
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O
XN
OO
X=
(1.67) (1.68) (1.69)
(1.70)(1.71)  
Reagents: i. MeLi/ZnCl2, Ni(cod)2 (10 mol %), Ti(O-
i
Pr)4, (57% (97:3 diastereomeric ratio)). 
Scheme 1.15: Montgomery’s Nickel Catalysed Cyclisation50 
 
 Naito’s synthesis of kainic acid (1.1) in 2000 used sulphur chemistry to install the tri-
substituted core (Scheme 1.16)
54
. Diene precursor (1.74) was built by combining (S)-
vinylglycinol (1.72) with hydroxyl sulphide (1.73), and cyclised cleanly to give a mixture of C-
4 isomers in a ratio of 2:3 in favour of (1.75). In this case it was shown that installation of an 
oxazolidinone ring actually impeded the cyclisation step leading to a recovery of starting 
material. Kainic acid (1.1) was obtained following a further seven steps. 
 
 
i) 
 27 
 
N
Ts
N
Ts
(1.74)
PhS
OMOM
OMOM
OMOM
NHTs
PhS
OH
+
(1.72)
(1.73)
(1.75)
N
Ts
OMOM+
(1.76)
SPh SPh
 
Reagents and Conditions: i. PPh3, DEAD, THF. ii. PhSH(cat.), AIBN, C6H6, Δ (95%, (1.75:1.76) (1:1.5)). 
Scheme 1.16: Naito’s Route54 
 
 Hoppe achieved a diastereoselective total synthesis of kainic acid in 2004 (1.1) by using 
a ()-sparteine (1.80) mediated asymmetric deprotonation of the carbamate (1.77), which then 
underwent a stereospecific intramolecular cyclisation to give the diastereomers (1.78 + 1.79) in 
a (8:2) ratio respectively (Scheme 1.17)
55
. He extended this work in 2005 to include an 
oxazolidinyl ring system, hoping to improve stereocontrol at the C-2 centre. Unfortunately as 
with Naito’s work this too proved unsuccessful56.   
N
(1.78)
O
O
NiPr2
N
H
N
H
H
(1.79)
+
(1.80)
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N
O
O
NiPr2
OTBSBn Bn
(1.77)
N
Bn
Cl O
NiPr2
O
OTBS
 
Reagents and Conditions: i. 
n
BuLi, (1.80), toluene, -78°C (83%, (1.78:1.79) (8:2)). 
Scheme 1.17: Hoppe’s Route55 
 
i) 
ii) 
i) 
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 In 2005 Lautens reported an enantioselective synthesis of kainic acid (1.1) with an 
overall yield of 15%
57
. He utilised a MgI2-mediated diastereoselective ring expansion of 
methylenecyclopropyl amide (1.81) in the presence of chiral sulphoxide (1.82) which, resulted 
in pyrrolidine (1.83) (Scheme 1.18). Kainic acids (1.1) remaining C-4 stereocentre was then 
incorporated after a diastereofacial hydroboration, followed by an oxidative work up to give the 
alcohol (1.84). It took a further laborious ten steps before kainic acid (1.1) was attained. 
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O
(1.81) (1.83)
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OMe
N
NPh2
O
(1.84)
S
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HO
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S
N
O
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Reagents and Conditions: i. MgI2, THF (78%); ii. 9-BBN, THF, 50°C then NaOH, H2O2 (91%). 
Scheme 1.18: Lauten’s Route57 
 
Poisson’s first stereoselective synthesis of kainic acid (1.1) came in 2005 and featured a 
diastereoselective enolate alkylation of ketone (1.85) to afford the intermediate (1.86). A chiral 
reduction gave the homo chiral diol (1.87) (Scheme 1.19)
58
. Further manipulation and 
displacement of the modified secondary alcohol, using an organocuprate procedure (developed 
by Anderson in a racemic synthesis of kainic acid (1.1)
59
), installed kainic acid’s (1.1) C-4 
isopropenyl group to give the kainic acid precursor (1.88).  
 
i) 
ii) 
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Reagents and Conditions: i. 
n
BuLi, HMPA, THF, -78 °C then BrCH2CO2Me, NaI, -40 °C (80% (dr 
16:1)); ii. L-Selectride, THF, -78°C. iii. NaBH4, EtOH, 0 °C (70% over 2 steps). 
Scheme 1.19: Poisson’s 1st Route58 
 
 Poisson presented a second synthesis of kainic acid (1.1) in 2006 (Scheme 1.20)
60
. A 
high pressure Diels-Alder reaction between Danishefsky’s diene (1.91) and the vinylogous 
malonate (1.89) from a modified trans-4-hydroxy-L-proline resulted in the kainate precursor 
(1.90), in 80% yield and 90% ee. Further elaboration yielded kainic acid (1.1) in almost 10% 
overall yield. This approach has similarities with previous work by Ohfune and Tomita in their 
total synthesis of  domoic acid (1.3)
22
;  
 
N
Boc
CO2Me
(1.90)
HMeO2C
MeO
OTMS
N
Boc
CO2Me
(1.89)
MeO2C
MeO
OTMS
(1.91)
 
Reagents and Conditions: i. (1.91), 20 °C, 15 Kbar, CH2Cl2 (80%, (90% ee)). 
Scheme 1.20: Poisson’s 2nd Route60 
 
 A formal synthesis by Madec and Poli in 2007 proceeded via an intramolecular 
palladium-catalysed allylic alkylation (Scheme 1.21)
61
. The cyclised pyrrolidone (1.93) was 
further functionalised through a Horner-Wadsworth-Emmons olefination, condensation with 
ethyl glyoxalate and subsequent reduction to intermediate (1.94), before following the same 
route as described by Ganem
37
.  
 
ii, iii) i) 
i) 
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(1.92) (1.93) (1.94)
(1.1)
N
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O N
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Reagents and Conditions: i. [Pd(C3H5)Cl]2 (5 mol%), dppe (12.5 mol%), 
n
Bu4NBr (10 mol%), KOHaq (4 
eqv), CH2Cl2-H2O (1:1), rt, 16 h. (quantitative) trans/cis >95:5. ii. Ref. 
37
. 
Scheme 1.21: Madec and Poli’s Route61 
 
 In 2007, Fukuyama demonstrated a total synthesis of kainic acid (1.1) whereby the 
trisubstituted pyrrolidine ring (1.97) was constructed using a ring-closing metathesis (RCM) 
upon an optically active acrylate (1.95) followed by an intramolecular Michael addition of the 
resultant α,β-unsaturated lactone (1.96) (Scheme 1.22)62. Both key reactions proceeded 
smoothly and further elaboration of bicyclic intermediate (1.97) yielded kainic acid (1.1) in 13% 
overall yield. 
 
O O
BocN
CO2Me
O O
BocN
CO2Me
N
Boc
CO2Me
O
H H
O
(1.95) (1.96) (1.97)  
Reagents and Conditions: i. Hoveda-Grubbs’ 2nd generation catalyst (0.8 mol%), Cl2(CH2)2Cl, Δ, 3d. 
(99%). ii. LiHMDS, -60°C, (95% (C-2 epimer = 91:9)). 
Scheme 1.22:  Fukuyama’s RCM Route62 
 
 Fukuyama follows up this synthesis with a 2
nd
 generation route in 2008, that proceeded 
via a one-pot sequential elimination-Michael addition of  β-amino-δ-lactone (1.99) formed from 
an inexpensive azetidinone starting material (1.98) (Scheme 1.23)
63
, whereby removing the 
need for an uneconomical RCM. The synthesis was completed in a similar fashion to his 
previous one in an overall yield of 14%. 
 
 
i) ii) 
i) ii) 
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H H
O
(1.97)(1.98) (1.99)  
Reagents and Conditions: i. LiHMDS (1eqv), CbzCl, DMF -60°C-rt, 20m. ii. LiHMDS (2.5eqv) -60°C. 
20min. (94% (C-2 epimer 92:8)). 
Scheme 1.23: Fukuyama’s 2nd Generation Route63 
 
 Tomooka discovered an interesting route to kainic acid (1.1) in 2008 that proceeded 
through a palladium catalysed Cope rearrangement of chiral planar amide (1.100) to provide 
solely the desired product (1.101) in 94% yield and high diastereoselectivity (92:8) (Scheme 
1.24)
64
. Selective hydroboration and an appropriate protecting group strategy gave access to 
intermediate (1.102) which, was converted into the desired C-2 carboxylation products (1.103) 
and (1.104) under control of external chiral ligand (1.105). Intermediate (1.103) could easily be 
separated from its diastereomer (1.104) through chromatography and derivatised to kainic acid 
(1.1). 
 
 
Reagents and Conditions: i. cat. PdCl2(PhCN)2, CH2Cl2, rt, (87% (>98% dr, >98% ee)). ii. 
s
BuLi, (1.105) 
Et2O, -78°C then ClCO2Me, -78°C, (84% (1.103:1.104 = 58:42)). 
Scheme 1.24: Tomooka’s Route64 
 
 Helmchen published a route in 2010 which uses an iridium catalysed allylic amination 
to construct the enyne precursor (1.109) required for an intramolecular Pauson-Khand reaction 
i, ii) 
i) 
 ii) 
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(Scheme 1.25)
65
. The cyclopentenone product (1.110) of this Pauson-Khand protocol was then 
elaborated to yield kainic acid (1.1) in an additional 6 steps. 
N
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O
OTBDMS
H
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OTBDMS
BocHN
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H2N
TBDMSO
OCO2Me
or
(1.106) (1.107)
(1.108)
(1.109) (1.110)
[Ir]cat
 
Reagents and Conditions: i. Co2(CO)8, CH2Cl2, rt, 4h. ii. Me3NO.2H2O, 4Å MS, rt, 4h (57%). 
Scheme 1.25 Helmchen’s Route65 
 
 The most recent example to be found in the literature was published by Fukuyama et 
al.
66
. Starting from (+)-carvone (1.111), the route proceeds via the formation of a stable 
iodolactone (1.112) which rigidifies the molecule and allows for a stereoselective alkylation to 
introduce the C-3 unit (Scheme 1.26). A reductive ring opening facilitated by zinc in acetic acid 
followed by cyclisation provided the desired cis-substituted lactam (1.115) which, through a 
selective reduction and nitrile addition gave precursor (1.116). A base hydrolysis and concurrent 
epimerisation of the C-2 centre gave access to kainic acid (1.1) in a 10.3% overall yield from 
(+)-carvone
66
. 
O
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O OMe
O OMe
CO2
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N
CO2Me
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tBu CO2H
NHCO2Me
CO2
tBu
(+)-carvone (1.111) (1.112) (1.113)
(1.114)(1.116)
N
CO2Me
CO2
tBu
(1.115)
O
I I
NHCO2Me
NHCO2Me
 
Reagents and Conditions: i. LiHMDS, THF, -78°C then BrCH2CO2
t
Bu (82%), ii. Zn, AcOH, EtOH, 0°C-
rt, iii. DEPC, Et3N, CH2Cl2, rt (60% over 2 steps). 
Scheme 1.26: Fukuyama’s Synthesis66 
 
 i, ii) 
 i) 
ii) 
iii) 
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1.2.5 Previous Syntheses of (-)-Domoic Acid (1.3) and (-)-Isodomoic 
Acid C (1.6) 
 
 Only one total synthesis of (-)-domoic acid has been reported; that of Ohfune and 
Tomita in 1982
22
. This approach uses Diels-Alder methodology to control the relative 
stereochemistries of both the C-3 and C-4 stereocentres by a [4+2] cycloaddition of unsaturated 
lactam (1.117) and siloxydiene (1.121) to yield bicyclic lactam (1.118) based on steric and 
electronic effects (Scheme 1.27)
22
. An oxidative cleavage of the cyclohexene ring in (1.117) 
was followed by a laborious sequence of functional group manipulations to provide (1.119). Use 
of an unstabilised ylid with predefined stereochemistry in a Wittig reaction gave the desired E-
alkene. The primary alcohol was then oxidised and esterified providing a protected domoic acid 
(1.120) whereby saponification and acid treatment complete the synthesis of an optically pure  
(-)-domoic acid (1.3). 
 
Reagents and Conditions: i. (1.121), toluene, 135˚C. ii. nBuLi (2 eqv), , iii. Jones oxidation. 
iv.CH2N2. 
Scheme 1.27: Ohfune and Tomita’s Route22 
 
In 2005 Clayden et al. published a synthesis of (-)-iso-domoic acid C (1.6)
67
, which 
followed their previous work on kainoids
68,69
. An asymmetric deprotonation and cyclisation of 
an N-benzyl benzamide (1.122) followed by in situ hydrolysis provided bicycle (1.123). A 
recrystallisation from ethyl acetate was needed to achieve an enantiomeric enrichment of 99% 
however the yield associated with this transformation was a mere 38% overall. Eleven routine 
steps followed including the conjugate addition of a mixed cuprate, a sodium 
CH2PPh3
OH
 ii, iii, iv) 
 i) 
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periodate/ruthenium chloride oxidation and the oxidation of a selenide to complete this 
uneconomical synthesis with an overall yield of 0.4% in 15 steps. 
 
MeO
N
O
Ph
O
N
O
Ph
H
H
Ph N
Li
(1.22) (1.23)  
Reagents and Conditions: i. a: THF, -78 to 20˚C. b: HCl, H2O, (62% (86% ee)). ii. Recrystallisation from 
AcOEt, (62% (99% ee)).  
Scheme 1.27: Clayden’s Route67  
 i), ii), iii) 
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CHAPTER 2: Results and Discussion 
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2.1 Project Aims 
There is a very real need to develop a process for creating analogues of kainic acid (1.1) 
and domoic acid (1.3) in order to find novel antagonists that could play neuroprotective roles 
and alleviate or halt the progression of a variety of CNS disorders. This project aimed to 
develop an efficient synthesis of kainic acid (1.1) which would lead to a synthesis of domoic 
acid (1.3) and novel kainates. Hitherto the syntheses that have been published in the literature 
have encountered difficulties either giving rise to multi-step syntheses resulting in unacceptably 
low yields of the kainates or mixtures of isomers. Many laboratories over the world have 
produced syntheses that are much longer and less efficient than the original work of Oppolzer
17
 
and there is still a need to develop a highly efficient route to optically pure (-)-α-kainic acid 
(1.1) and other biologically important compounds containing the kainate motif. 
 
Initially a 1-pot procedure to form the kainate ring system was planned. This involved 
the reaction of a suitably substituted isocyanate with an epoxide and then to extend this 
approach to other ring systems (Scheme 2.1). 
 
The following points formed a guideline for the project to adhere to: 
 
 Use a short and novel approach to give a range of substituted kainates involving a 
simple condensation step. 
 Proceed via an ene-reaction involving a substituted heterocyclic 1,6-diene to furnish 
kainate core in a stereoselective manner. 
 Use the heterocyclic ring template to carry out a series of intermolecular metathesis 
reactions to furnish optically pure (-)-domoic acid (1.3) and other novel kainates 
(Scheme 2.1). 
 Synthesis must be: 
o Economical (using cheap materials/reclaimable catalysts) 
o Efficient (high yielding chemistry) 
o Easily scalable 
o Avoid the use of toxic substrates where possible  
o Avoid use of toxic or heavy metals where possible 
o Use minimal chromatography 
o Avoid the use of protecting groups 
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Scheme 2.1: Initial Guidelines for Project 
 
2.2 Chemistry of Ene-Precursor Oxazolidinone (2.1) 
 
N
O
O
(2.1)
CO2Et
 
Figure 2.1: Ene-Precursor Oxazolidinone (2.1) 
 
2.2.1 Route 1 
2.2.1.1 Retrosynthetic Analysis 1 
 Retrosynthetic analysis of oxazolidinone (2.2) led to the hypothesis that the 
combination of allyl isocyanate (2.4) and epoxy allylic methyl ester (2.5) in a one-pot 
cyclisation/ene-reaction via the oxazolidinyl intermediate (2.3), would give ene-precursor (2.2) 
(Scheme 2.2). Oxazolidinone (2.3) is similar in structure to Oppolzer and Thirring’s 1,6 diene 
(1.22) and could be used in the already well established ene-reaction route
17,34,35,37,40
. To 
generate the desired stereochemistry at the C-3 and C-4 positions in the natural product (1.1) the 
transition state for the ene-reaction should adopt the least sterically congested approach. Due to 
this steric crowding the cis hydrogens (shown in green) on the C-3/C-4 carbon atoms must both 
point up (Figure 2.2). 1-Bromo-3-methyl-2-butene (2.8) and acrolein (2.7) are both 
commercially available and through reported conditions can give access to the desired 
precursors of this synthesis
70-73
. 
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Scheme 2.2: Retrosynthetic Analysis 1 
 
 
Figure 2.2: 3D Diagram of Ene-Precursor (2.3) 
 
2.2.1.2 Model Studies 
 It has been known since 1958 that the reaction between isocyanates and 1,2-epoxides 
catalysed by a Lewis acid furnishes 2-oxazolidinones
74
.
 
Combination of commercially available 
allyl isocyanate (2.9) with 1,3-epoxybutadiene (2.10) using a procedure developed by Herweh
75
 
formed an inseparable mixture of the desired 4-substituted 2-oxazolidinone (2.11) and undesired 
5-substituted 2-oxazolidinone (2.12) in 60% yield and ratio of 1:3 respectively (Scheme 2.3).  
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Reagents and Conditions: i. DMF, LiCl, reflux 6h, (60% (2.11:2.12 = 1:3)). 
Scheme 2.3 Formation of Oxazolidinones (2.11) and (2.12)  
 
A mechanism for the formation of oxazolidinones (2.11) and (2.12) was proposed 
(Scheme 2.4) whereby the epoxide (2.10) is activated by the lithium chloride Lewis acid 
allowing the lone pair on the isocyanate nitrogen (2.9) to attack at one of two positions on the 
oxirane ring (shown by arrows a and b). The electrophilic carbonyl carbon on the isocyanate is 
then attacked in situ by the lone pair of the oxiranyl oxygen to form the 4-substituted or 5-
substituted oxazolidinone products (2.11) and (2.12). Both isomers were assigned by 
comparison of the 
1
H-NMR spectra of the mixture of oxazolidinones (2.11) and (2.12) with 
known 
1
H-NMR literature values for the 4-substituted oxazolidinone (2.11)
76
; no literature data 
was available for compound (2.12). 
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Scheme 2.4: Proposed Mechanism for Formation of (2.11) and (2.12) 
 
 Attempts to optimise the exclusive formation of model oxazolidinone (2.11) utilised a 
range of different solvents and catalysts, however none of the alternatives attempted revealed a 
more efficient process (Table 2.1). Similar isomeric ratios were seen by 
1
H-NMR.  
 
 
 
i) 
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Entry Solvent Catalyst Total Yield (2.11+2.12) 
1 DMF CaCl2 NONE FOUND 
2 THF BF3 NONE FOUND 
3 THF Pd(PPh3)4 NONE FOUND 
4 MeCN LiCl NONE FOUND 
5 DMSO LiCl 18% 
6 DMF LiCl 60% 
Table 2.1: Formation of Model Oxazolidinones (2.11 and 2.12) 
 
 When using the highly reactive chlorosulfonyl isocyanate (2.13)
77
 it was possible to 
achieve oxazolidinone formation under vastly milder reaction conditions (Scheme 2.5). The 
reaction could advance in dichloromethane at room temperature without the need for a Lewis 
acid catalyst. The selectivity of this combination was however not advantageous and solely the 
undesired 5-substituted 2-oxazolidinone (2.14) was obtained in 51% yield. Investigation of this 
direction continued forward to prove whether the same selectivity would be seen in the real 
system. 
 
 (2.10)(2.13) (2.14)
HN
O
OO
NCO
+S
Cl
O O
 
Reagents and Conditions: i.CH2Cl2, 0-25°C 6 h, then KIaq, 0°C, (51%). 
Scheme 2.5: Formation of (2.14) 
 
2.2.1.3 Precursor Synthesis 
 The chemistry employed to construct epoxide (2.6) is well established, starting with a 
base catalysed epoxidation of acrolein (2.7) (Scheme 2.6)
70
. A subsequent Wittig olefination
78,79
 
of the crude reaction mixture followed by vacuum distillation gave a 1:2 mixture of cis:trans 
geometric isomers in 46% yield. This method avoided the difficult isolation of glycidaldehyde 
(2.15)
71
. Isocyanate (2.4) was formed in 51% yield by combining commercially available 3,3-
dimethylallyl bromide (2.8) and silver cyanate
72,73
. The volatility of isocyanate (2.4) under 
vacuum and polymerisation at higher temperatures yielded purification issues however, 
compound (2.4) was carried through to the next step while a new approach to avoid these 
problems was sought. 
 
 i) 
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O
O
(2.15)
CO2Me
O
(2.16)
O
(2.7)
 
 
Br
(2.8)
NCO
(2.4)  
Reagents and Conditions: i. H2O2/H2O, 1M NaOH, rt, ii. (C6H5)3P=CHCO2CH3, MeOH 0°C-rt, overnight 
(46% from acrolein (cis:trans 1:2)), iii. AgOCN, diethyl ether, rt, overnight (51%). 
Scheme 2.6: Formation of Precursors (2.16) and (2.4) 
 
2.2.1.4 Attempted Formation of Racemic Oxazolidinone (2.17) 
 
N
O
O
CO2Me
(2.17)  
Figure 2.3: Oxazolidinone (2.17) 
 
 When the cycloaddition of precursors (2.4) and (2.16) was attempted, issues arose with 
the extraction of products on workup when using lithium chloride as a catalyst. This was 
thought to be caused by the presence of a partially water soluble urea formed from hydrolysed 
isocyanate
80
 which caused the generation of a thick emulsion. Calcium chloride was used as an 
alternative and the reaction between epoxide (2.16) and isocyanate (2.4) progressed in an 
unsatisfactory 4% yield of new oxazolidinone (2.18); formed as one major diastereomer from 
1
H-NMR evidence (Figure 2.4).  The molecule had undergone a Michael addition of Cl
-
 
(displaced from calcium chloride Lewis acid by the epoxide oxygen) to the α,β-unsaturated ester 
(Scheme 2.7). Examination of molecular models predicts the major diastereomer to have the 
chlorine atom pointing up in space. Due to the poor yield of chlorinated oxazolidinone (2.18) no 
further work was attempted on this molecule as it could not serve as a precursor to kainic acid 
(1.1) and hence the structure has not been confirmed. 
 
  i)   ii) 
  iii) 
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Figure 2.4: Chlorinated Oxazolidinone (2.18)  
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Scheme 2.7: Michael Addition of Chlorine Eliminated from Calcium Chloride 
 
 The next logical progression was to investigate the avenue of Lewis acid catalysts using 
triflate salts; in order to prevent the 1,4 nucleophilic addition of chlorine as discovered 
previously, increase yield and allow formation of our target ene-precursor (2.17). Scandium 
triflate failed to assist the cycloaddition and after 6 hours only starting material could be seen by 
TLC. Silver triflate was then tried in 10 mol%, under the standard reaction conditions,
 
this 
unfortunately culminated in solely the undesired 5-substituted 2-oxazolidinone (2.19) being 
formed in a mere 17% yield (Figure 2.5). This highly unreliable reaction carried out in 
darkened glassware failed to provide a greater yield notwithstanding numerous changes to 
reaction protocol. It can also be noted that any attempts to scale up on the reaction from 
approximately 2 mmol scale (around 250 mg of 2.16) saw a decrease in yield to circa 7%. The 
results are listed below (Table 2.2). 
 
N
O
O
(2.19)
CO2Me
 
Figure 2.5: Undesired Oxazolidinone (2.19) 
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Entry Reagents and Conditions Catalyst % Yield (2.19) 
1 DMF, 1:1 (2.16:2.4) ScOTf No Reaction 
2 DMF, 1:1 (2.16:2.4) AgOTf 17% 
3 DMF, 1:1.5 (2.16:2.4) AgOTf 7% 
4 DMF, 1.5:1 (2.16:2.4) AgOTf 7% 
5 CH2Cl2, 18 h reflux, AgOTf No Product found 
6 1-methyl 2-pyrrolidinone AgOTf Decomposition of SM by TLC 
7 DMSO AgOTf <5% 
8 MeCN AgOTf No Reaction 
Table 2.2: Formation of Oxazolidinone (2.19) 
 
 A change in route brought about by the aforementioned purity issues of isocyanate (2.4) 
and the lack of selectivity of the cycloaddition reaction when applied to the real system, planned 
to utilise an alkylation of the free NH on oxazolidinone (2.20) formed through the combination 
of chlorosulfonyl isocyanate (2.13) and epoxide (2.16) (Scheme 2.8). However, this had 
complications as not only did the reaction halt prematurely, but unsurprisingly the major 
products recovered were the undesired 5-oxazolidinone (2.21) and hydrolysed starting material. 
A variety of solvents and reaction temperatures were tested (Table 2.3) including the use of 
various equivalents of 1,2-epoxyhexane as an acid scavenger. To date the correct strategy has 
remained elusive and the highest yield of oxazolidinone (2.21) seen was 17%.  
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Reagents and Conditions: i. See Table 2.3 
Scheme 2.8 Formation of Oxazolidinone (2.21) 
 
 
 
 
i) 
i) 
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Entry Reagents and conditions % Yield (2.21) 
1 CH2Cl2, 0°C-rt, 4 h, sat. KI(aq) 17% 
2 CH2Cl2, -10°C-rt, 4 h, sat. KI(aq) 7% 
3 CH2Cl2, -78°C-rt, 4 h, sat. KI(aq) 15% 
4 CH2Cl2, -10°C-rt, dihydrogen phosphate(aq) 7% 
5 Diethyl ether, -60°C-rt, 3 h None Found 
6 Nitromethane, -10°C-rt, 3 h None Found 
7 Toluene, -10°C-rt, 3 h None Found 
8 CH2Cl2,, 60°C-rt, 3:4 (1,2-epoxyhexane : (2.13)) Mixed spot of (2.21) and cyclised 
epoxyhexane product 
9 CH2Cl2,, 60°C- rt, 3:1.05 (1,2-epoxyhexane : (2.13)) Mixed spot of (2.21) and cyclised 
epoxyhexane product 
10 Neat Addition halted as hazardous 
Table 2.3: Formation of Oxazolidinone (2.21) 
 
2.2.2 Route 2 
2.2.2.1 Retrosynthetic Analysis 2 
 Due to continuing difficulties with expensive reagents leading to low yields of 
intermediates, it was illogical to move forward with the previous synthetic approach and a new 
route to the ene-precursor molecule (2.3) was devised. As shown in the retrosynthetic analysis 
(Scheme 2.9) it was hypothesised that the target precursor (2.3) could be constructed with the 
desired stereochemistry at the C-2 carbon from a base catalysed intramolecular cyclisation of 
chiral aziridine (2.22) (Scheme 2.10). It was envisaged that this intermediate would be 
accessible by alkylation of the aziridinyl nitrogen (2.23) constructed from a Staudinger 
reaction
81
 on the asymmetric epoxide (2.24). Following the work as described by Pak and Lee, 
allylic alcohol (2.25) could be constructed in good yield through a reductive cleavage of alpha 
unsaturated ester (2.26) mediated by magnesium in methanol
82
. Sequential deprotection of ketal 
(2.27) then revealed glycerol (2.28) as a cheap alternative start material.  
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Scheme 2.9: Retrosynthetic Analysis 2 
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Scheme 2.10: Base Catalysed Cyclisation of Aziridine (2.22) 
 
2.2.2.2 Chemistry of Aziridine (2.29) 
 
CO2Me
TBSO
HN
(2.29)  
Figure 2.6 Aziridine (2.29) 
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 The first step of this new route involved a straightforward acid catalysed protection of 
glycerol (2.28) with acetone. Following an improved preparation of Fischer’s original 
procedure
83
 illustrated by Newman and Renoll in 1945
84 
it was possible to make isopropylidene 
glycerol (2.27) in 95% yield (Scheme 2.11). Next a modification of Ireland and Norbecks one-
pot Swern oxidation/Wittig procedure was used to  convert the protected glycerol (2.27) into the 
desired allylic ester (2.30)
85
. This reaction proceeded smoothly on a multi-gram quantity scale to 
provide the unsaturated ester (2.30) as a mixture of cis/trans-isomers in a satisfactory 72% yield 
over the two steps and ratio of 10:77 respectively. These isomers are fully separable via column 
chromatography however, this is unnecessary for the next step. To furnish the necessary allylic 
alcohol (2.25) it was fitting to follow the reductive cleavage concept of using magnesium in 
methanol at -23 °C exposed by Pak et al. in 1993
82
. Following several unsuccessful attempts it 
was found that the addition of silicon carbide (carborundum) was necessary to activate the 
magnesium powder and initiate the radical production.  This reaction gives as stated in the 
paper, solely the desired trans-alcohol due to the steric hindrance exerted by dioxanyl group on 
the conformation of the radical anion. This steric property must in turn control the 
stereochemistry of newly formed double bond
82
. The low yield of 64% this step has been 
attributed to the laborious task of purification due to the formation of extremely fine magnesium 
oxide which clogged any filtering media it came in contact with. 
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Reagents and Conditions: i. acetone, pentane, pTSA, Δ (temp @ head 31°C), 35 h (95%), ii. (COCl)2, 
DMSO, Et3N, (C6H5)3P=CHCO2CH3, CH2Cl2, -78°C to -1°C,  overnight (74% (cis:trans = 77:10)), iii. 
Mg, carborundum, MeOH, -23°C, 2 h (64%). 
Scheme 2.11: Formation of Allylic Alcohol (2.25) 
 
 The enantioselective epoxidation of allyl alcohol (2.25), as according to the modified 
procedure developed by Sharpless proceeded extremely sluggishly at -20°C with (+)-
diisopropyl L-tartrate and did not reach completion even after 31 days
86,87
 (Scheme 2.12).  
Following a ferrous sulphate workup to destroy excess peroxide, the desired epoxy alcohol 
(2.24) was obtained using column chromatography on neutral silica in good yield (75%) based 
on recovered starting materials. The slow reaction rate is believed to have arisen due to 
coordination of the ligated titanium species to the additional oxygen functionality in the 
molecule. Epoxide formation would only have resulted when the titanium species coordinated to 
the appropriate alcohol functional group next to the double bond. With epoxy alcohol (2.24) in 
i) ii) iii) 
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hand the synthesis moved forward by protecting the alcohol group with a tert-butyldimethylsilyl 
moiety to provide silyl ether (2.31)
88
.  
 
 The Staudinger protocol was next applied to construct aziridine (2.29) via hypothesised 
regioisomers (2.32 + 2.33)
81
. The first step was to combine epoxide (2.31) with sodium azide. 
Interestingly it was shown that in fact only formation of the azido alcohol (2.32) was possible as 
the azide group of the alternate organic azide (2.33) simply eliminated to form enone (2.33). 
The optimal method followed Zwanenburg and Nolte’s protocol using ammonium sulphate as 
an additive and gave a return of 47% of useable intermediate (2.32) and 21% of enone (2.34)
89
. 
An analogous result was seen when using ammonium chloride however the overall yields were 
marginally less
90
. When using sodium azide not in combination with an ammonium salt solely 
the elimation product (2.34) was produced in a 51% yield
91
. The second part of Staudinger’s 
protocol was to treat the organic azide with triphenylphosphine in acetonitrile and heat to reflux, 
producing the target aziridine (2.29) in an acceptable 79% yield. It must be noted that the 
enantiomeric enrichment calculations on the epoxy alcohol (2.24) were unfeasible using the 
standard Moshers ester method as under the reaction conditions molecular decomposition 
occurred. 
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Reagents and Conditions: i. Ti(O
i
Pr)4, (+)-DIPT, TBHP, 4Å MS, CH2Cl2, -20°C, 31 Days, (75%), ii. 
TBSCl, imidazole, DMAP, CH2Cl2, 0°C, 1 h, (96%), iii. NaN3, (NH4)2SO4, MeOH/H2O (v/v 10:3) (47% 
(2.32)), (21% (2.34)), iv. PPh3, MeCN, Δ, 5h, (79%) 
Scheme 2.12: Formation of Aziridine (2.29) 
 
i) 
ii) iii) 
iv) 
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 Deprotection of the silyl group on aziridinyl compound (2.29) was attempted regardless 
of the foreseen complications with any subsequent chemistry involving either, the carbonate 
formation from the revealed alcohol or possible alkylation of the nitrogen. Both of these steps 
were expected to be complicated due to labile acidic nature of the protons alpha to the carbonyl 
group. TBAF caused molecular destruction presumably, as stated by Corey, due to the 
sufficiently basic nature of F
-
 ion in tetrahydrofuran affecting a sensitive system
92
. In light of 
this, the removal of TBS protecting group was attempted with hydrofluoric acid. Under these 
conditions the reaction failed to yield any desired product. 
 
2.2.3 Route 3: A Second Generation Route 
2.2.3.1 Retrosynthetic Analysis 3 
 To circumvent the problem of the acidic nature of the α-protons due to the carbonyl 
functionality present in aziridine (2.29), the synthesis was modified by simply replacing the 
ester group with an alcohol. The retrosynthetic schematic delineates a route also employing 
Staudinger’s method of aziridine formation (Scheme 2.13). Sequential disconnections from 
cyclisation precursor (2.35) exposed a protected diol (2.36). The free NH moiety of this 
molecule could be alkylated and, through use of an appropriate deprotection, carbonate 
formation and oxidation strategy, be manipulated to provide the target precursor (2.35). Moving 
linearly backwards through a Staudinger protocol on the enantiopure epoxide (2.37) formed 
from allylic alcohol (2.38) subsequent disconnections then revealed 3-butyn-1-ol (2.41) as an 
appropriate starting material for this synthesis. 
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Scheme 2.13: Retrosynthetic Analysis 3 
 
 
2.2.3.2 Chemistry of Aziridine (2.42) 
 
THPO
HN
OTIPS
(2.42)  
Figure 2.7: Aziridine Intermediate (2.42) 
 
 Following the work of Razon et al. the alcohol function of 3-butyn-1-ol (2.41) was 
protected as its triisopropylsilyl ether (2.40) in quantitative yield (Scheme 2.14)
93
. A high 
yielding homologation step followed and subsequent lithium aluminium hydride reduction of 
the resulting propargylic alcohol (2.39) constructed trans-allylic alcohol (2.38) in 98% yield
93
. 
A facile Sharpless asymmetric epoxidation utilising (+)-diisopropyl L-tartrate
87
 gave the novel 
epoxy alcohol (2.37) in 67% yield and an enantiomeric excess of 64%. When using (+)-diethyl 
L-tartrate the reaction timing increased to around eight days. The yield associated with this 
epoxidation also increased to 76% however the enantiomeric excess of this epoxide fell to 22% 
ee. To determine and compare the enantiomeric excesses of the epoxides (2.37) resulting from 
the reaction of alkene (2.38) with DIPT and DET the Moshers esters of the epoxide mixtures 
from each reaction were synthesised following the work of Sharpless
94
. 
1
H-NMR analysis 
focused on the terminal methylene protons of the primary epoxy alcohols. These protons were 
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observed as a diastereomeric pair of doublets of doublets (dd) around δ 4.65 (see appendices for 
1
H-NMR spectra). The downfield pair was compared by integration to determine the 
enantiomeric excess.  A racemic mixture was not prepared and the 
19
F-NMR gave inconclusive 
data. 
 
(2.41) (2.40) (2.39)
HO
(2.38)
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Reagents and Conditions: i. TIPSOTf, Et3N, CH2Cl2, 0°C, 16 h (>99%), ii. 
n
BuLi, paraformaldehyde, 
THF, -78°C, 6 h (92%), iii. LAH, THF, -10°C, 16 h (98%), iv. Ti(O
i
Pr)4, (+)-DIPT, TBHP, 4Å MS, 
CH2Cl2, -20°C, 16 h (67% and 82%ee).  
Scheme 2.14: Formation of Epoxy Alcohol (2.37) 
  
 Two protecting group strategies were initially explored with respect to the free alcohol 
function of epoxide (2.37). It was postulated that an acid labile triethylsilyl protecting group 
would allow for easy removal following the aziridine formation. It was also pertinent to apply a 
carbonate group to this end of the molecule in the hope that it may remove the need for further 
deprotection steps later in the synthesis. RuCl3/NaIO4 should be sufficiently mild enough to 
oxidise the primary alcohol in presence of both the TES moiety and carbonate functionality
95
. 
The silyl protection of (2.37) with TES chloride progressed in 97% yield to give di-protected 
diol (2.43)
92
 and the carbonate formation by combination with ethyl chloroformate gave a 95% 
return of carbonate (2.44)
96
 (Scheme 2.15). On investigation both starting materials (2.43) and 
(2.44) gave complex inseparable mixtures of compounds under the standard Staudinger reaction 
conditions. Column chromatography was used to remove the major polar and non polar 
impurities; closer inspection of the 
1
H-NMR spectra of the mixture of products revealed that the 
major product had both of these groups displaced by the azide anion. This was surprising in the 
case of the carbonate group which should have been stable to attack from such a nucleophile
95
. 
However, less so for the TES group which shares many similarities in reactivity with the 
trimethyl analogue
95
.  Simultaneous opening of both epoxides was also seen in sparing 
quantities. This deduction is based on shifts in upfield CH2 peaks representative of the changes 
in environment to protons situated within appropriate distances of the epoxide ring and 
confirmed by the infrared spectrum which showed the presence of both azide and alcohol 
i) ii) 
iii) 
iv) 
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stretches. The sulphate additive was imperative to the reaction and when omitted starting 
materials could be recovered. The use of these labile appendages was abandoned and the 
tetrahydropyranyl group was chosen for the next strategy.  
 
HO
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inseparable products
 
Reagents and Conditions: i. TESCl, imidazole, CH2Cl2, 0°C, 1 h, (97%) ii. CH3OCOCl, pyridine, DMAP, 
CH2Cl2, 3 h (95%) iii. NaN3, (NH4)2SO4, MeOH/H2O (v/v 10:3). 
Scheme 2.15: Silyl and Carbonate Protections 
 
 Fortuitously the tetrahydropyranyl protection of the primary alcohol (2.37) proceeded 
smoothly in 93% yield
97
. The use of Zwanenburg and Noltes’ modified Staudinger reaction on 
the mixture of diastereomers (2.45) gave both azido alcohols (2.46) and (2.47) in a combined 
yield of 78% (Scheme 2.16)
89
. Finally the mixture of organic azides was reacted with 
triphenylphoshine in refluxing acetonitrile which gave an almost quantitative conversion to the 
aziridine target molecule (2.42). 
HO
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OTIPS THPO
O
(2.45)
OTIPS
THPO
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THPO
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OH
OH
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N3
THPO
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+
Reagents and Conditions: i. DHP, PPTS, CH2Cl2, rt, 36 h (93%), ii. NaN3, (NH4)2SO4, MeOH/H2O (v/v 
10:3) (78%), iii. PPh3, MeCN, Δ, 4 h (96%). 
Scheme 2.16: Formation of THP Protected Aziridine (2.42) 
 
i) 
ii) 
iii) 
iii) 
i) ii) 
iii) 
 52 
 
2.2.3.3 Alkylation and Deprotection Attempts on Aziridine (2.42)  
 Investigation into the alkylation of aziridine (2.42) tested the theoretical aspects behind 
the modified route and presented a new series of problems. Using Aggarwal’s published method 
for alkylation of aziridines
98
; the aziridine (2.42) was heated with one and a half equivalents of 
potassium carbonate and a catalytic quantity of 18-crown-6 ether before addition of the 
bromide. Under these conditions two closely overlapping spots appeared by TLC. Neither of 
these products could be fully separated by column chromatography nonetheless, it was still 
possible to observe the presence of a prenyl chain. Submission of the associated masses of these 
compounds showed that they had additional molecular weight in the region of forty-four mass 
units when compared with the expected mass of the alkylated aziridine. The infrared analysis 
revealed the unmistakable carbonyl stretch at 1730cm
-1
 and confirmed that both N-alkylation 
and carbon dioxide insertion into the nitrogen centred 3-membered ring had occurred to form 
the “hypothesised” carbonylated products (2.48) and (2.49) (Scheme 2.17).  Next, basic 
amberlyst
®
 A21 ion exchange resin was used to assist in the desired alkylation step but again a 
similar result was recorded. Given that this sequence resulted in multi-component reaction 
products and the resulting structures isolated did not have the correct mass we abandoned this 
route and no further separations ie. by HPLC were attempted and hence these compounds have 
not been unequivocally assigned. A mechanism for the insertion of carbon dioxide was 
postulated whereby the aziridinyl nitrogen lone pair bonded to the electrophilic carbon of 
carbon dioxide (Scheme 2.18). The intermediate formed could then cyclise at either of the two 
major electrophilic sites (shown by arrows a and b) to form postulated products (2.48) and 
(2.49). The mechanism would be the same regardless of whether the alkylation step had taken 
place first. 
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Reagents and Conditions: i. 1-bromo-3-methyl-2-butene, 18-crown-6, K2CO3, MeCN, Δ, 2 h (No SM by 
TLC) or 1-bromo-3-methyl-2-butene, Amberlyst
®
 A21, CH2Cl2, rt, 3h (No SM by TLC). 
Scheme 2.17: Formation of Postulated Products (2.48 and 2.49) 
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Scheme 2.18: Proposed Mechanism of CO2 Insertion 
 
 Undeterred by this complication the alkylation step was left behind with the belief that 
the sidechain could be coupled to our molecule after the predicted intramolecular cyclisation. 
Attention turned to the deprotection of the THP moiety. Acidic and reductive methods of 
removal were ruled out due to the sensitive groups present in the intermediate (2.42) so Lewis 
acid catalysis was the clear choice. Decaborane is known to make adducts with Lewis bases 
such as amino groups so this was immediately ruled out and the widely known method of 
magnesium bromide in diethyl ether was attempted first. Both stirring the mixture at room 
temperature and heating to reflux left the starting material untouched. Magnesium bromide 
diethyl etherate was also shown to be totally ineffective under the conditions previously 
described. Next it was decided to stir the aziridine with montmorrilonite K-10. This clay, named 
after Montmorrillon in France, is a mixture of metal silicates and has shown use in the 
deprotection of THP ethers when combined with some form of oxidiser
95
. However, it was 
proposed that it may in fact be able to remove the THP group on its own in a sufficiently mild 
manner to withstand sensitive substrates; but this procedure also failed. The route now proving 
uneconomical and inelegant and involving a variety of laborious protection and deprotection 
i) 
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steps was abandoned and concentration shifted toward another more successful route that had 
been in evaluation parallel to this direction (see ch. 2.1.5). 
2.2.4 A Short Detour  
2.2.4.1 Retrosynthetic Analysis 4 
 Intrigued by the observation of molecular carbon dioxide insertion into the aziridinyl 
carbon-nitrogen bonds present in intermediate molecule (2.42) a short exploration began to 
uncover whether this could serve as a simple and quick way to access the key precursor (2.50). 
From the retrosynthetic analysis (Scheme 2.19) it was clear that intermediate (2.52) could be 
formed by inserting a molecule of CO2 into the aziridine ring (2.53) providing the correct 
selectivity was observed. A few simple disconnections reveals D-serine (2.55) which, by 
applying the work of Baldwin can be transformed into the enantiopure trityl protected aziridine 
(2.54) through some facile functional group manipulations and a ring closure
99
. 
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Scheme 2.19: Retrosynthetic Analysis 4 
 
2.2.4.2 Model Study 
 Methyl (S)-(-)-1-tritylaziridine-2-carboxylate (2.53) as synthesised from D-serine (2.54) 
is commercially available and was purchased directly from Sigma-Aldrich
®
 to test the feasibility 
of this route (Scheme 2.20). Carboxylate (2.53) was reduced in situ with diisobutylaluminium 
hydride to aldehyde (2.55) before undergoing a consecutive Horner-Wadsworth-Emmons 
olefination following the protocol highlighted by Fujii in 1995
100
. This provided us with the 
allylic precursor (2.52) in 86% yield over the 2 steps. Pinhas successfully utilised the ring 
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expansion of aziridines to cyclic carbamates with addition of a lithium iodide under a high 
pressure of gaseous CO2
101
. He showed that a 2:1 mixture of 4-substituted 2-oxazolidinones 
(2.58) and 5-substituted 2-oxazolidinones (2.59) could be achieved in high yields when R1 and 
R2 are alkyl groups (Scheme 2.21).  This is the opposite selectivity of the cyclisations between 
isocyanates and epoxides
75
. Pinhas also showed that if R1 is an alkyl and R2 is a phenyl group 
that exclusively the 5-substituted 2-oxazolidinone regioisomer (2.59) was formed. The paper 
concentrates on a select sample of substrates and unsure whether regioselectivity is utterly 
dependant on the inductive effects of substituent groups on the starting molecule, it was decided 
to see if this undesirable selectivity would be caused by having another electron withdrawing 
group at the R2 position instead of a phenyl as with the allylic intermediate (2.52).  
 
To achieve this transformation aziridine (2.52) was dissolved in tetrahydrofuran and one 
equivalent of sodium iodide was added. The entire vessel (heavy walled vial with a threaded 
Teflon
®
 plug or stainless steel ‘bomb’) was then cooled to minus seventy-eight degrees Celsius 
and thirty five equivalents of powdered dry ice (carbon dioxide) were added before screwing the 
lid down and placing behind a blast shield to warm to room temperature.  After two days the 
vessel was again cooled and the built up pressure carefully released before working up with 
10% sodium bisulfite. On analysis the hypothesis was confirmed and solely oxazolidinone 
(2.56) was formed in 73% yield (Scheme 2.20).  This structure can be confirmed as the 
chemical shift of the proton beta to the carbonyl group in compound (2.56) lies at 6.85 ppm. If 
the alternative 5-substituted structure was formed this peak would be much further upfield due 
to increased shielding effects of the trityl group.  
 
 
Reagents and Conditions: i. DIBAL-H, THF, -78°C, 2 h then ii. Na
+
 salt of (EtO)2P(O)CH2CO2Et,THF, 
rt, overnight (86%), iii. NaI, CO2, Sealed Vial, THF, rt, 2 days (73%). 
Scheme 2.20 Formation of Oxazolidinone (2.56) 
 
N
(2.57)
R1
R2
R1N
OO
R2 R1N
OO R2
+
(2.58) (2.59)  
Reagents and Conditions: i. LiI, CO2, sealed vial, rt, overnight. 
Scheme 2.21: Pinhas’ Oxazolidinone Formation101 
 
i) ii) iii) 
i) 
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2.2.5 Final Route to Ene-Precursor (2.1) 
2.2.5.1 Retrosynthetic Analysis 5 
 The final analysis unveiled a short, concise route to precursor (2.1) (Scheme 2.22) that 
could provide an economically viable access to both of the kainate targets of this thesis. The 
allylic side chain of compound (2.1) could be installed following a similar 
reduction/alkenylation rationale used previously on aziridine (2.53) (see ch. 2.1.4). An 
alkylation brings us back to oxazolidinone (2.61) which can be constructed by the combination 
of the hydrochloride salt of D-serine methyl ester (2.62) and either phosgene or triphosgene. 
This again reveals D-serine (2.54) as a suitable starting material to our target molecule (2.1). 
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Scheme 2.22: Retrosynthetic Analysis 5 
 
2.2.5.2 Chemistry of the Ene-Precursor (2.1) 
 The esterification of D-serine with acidified methanol proceeded smoothly to furnish 
ester (2.62) in an 89% yield (Scheme 2.23)
102
. With the hydrochloride salt (2.62) in hand a 
minor adjustment of Nudelman’s protocol103 was used to react with triphosgene and 
quantitatively convert (2.62) to the core oxazolidinone (2.61). The next step was to investigate 
the N-allylation of compound (2.61). Another paper published by Nudelman et al. in 1994
104
 
showed that the alkylation should proceed easily with sodium hydride in dimethylformamide. 
Unfortunately the yields recorded with 3,3-dimethylallyl bromide were initially vastly lower 
than hoped for at around 44%. Following an exploration into a few alternative solvents such as 
tetrahydrofuran
105
 (11-49% yield depending on the batch of sodium hydride used) and diethyl 
ether (21% yield), an optimal 4:1 mixture of THF and DMF was reached as a reaction solvent.  
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The low yields and inconsistency of this step can be attributed to the low solubility of the 
sodium salt of intermediate (2.61) in THF and diethyl ether. Addition of DMF as a co-solvent 
aided solvation and allowed for complete deprotonation before the addition of prenyl bromide. 
With these vital adjustments, the yield associated with this previously uneconomical step 
increased to a more manageable 78%.  Fujii’s DIBAL-H reduction100 and a synchronal Wittig 
olefination complete the synthesis of the previously unknown key intermediate (2.1). The 
1
H-
NMR of the Ene-precursor molecule is shown below (Figure 2.8).   
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Reagents and Conditions: i. CH3COCl, MeOH, Δ, 3 h (89%), ii. Et3N, triphosgene, CH2Cl2, 0°C-rt, 24 h 
(quantitative),  iii. NaH THF:DMF (4:1 v/v), 1-bromo-3-methyl-2-butene, 0°C-rt, 16 h (78%), iv. a) 
DIBAL-H, CH2Cl2, -78°C b) NH4Cl, (C6H5)3P=CHCO2CH3, -78°C-rt, 18 h (83%).  
Scheme 2.23: Formation of Ene-Precursor (2.1) 
 
 
 
 
 
 
 
i) ii) 
iii) 
iv) 
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Figure 2.8: 1H-NMR of Ene-Precursor Compound (2.1) 
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2.32 Investigating the Synthesis of Kainic Acid (1.1) and Domoic Acid 
(1.3) 
2.3.1 Retrosynthesis 
 It was envisaged that rapid progress towards kainic acid (1.1) and domoic acid (1.3) 
could be made utilising an intramolecular ene-reaction on the key precursor (2.1) (Scheme 
2.24). The synthesis now splits into two lateral routes. Ene-product (2.65) could undergo a cross 
metathesis of the isoprenyl double bond to install an octadienic sidechain allowing access to 
domoic acid precursor (2.68). To reach the final targets would then require parallel base 
mediated carbamate ring opening, re-esterification and N-protection of products (2.65) and 
(2.68) to furnish alcohols (2.64) and (2.67). Careful oxidation of the primary alcohol 
functionality on both molecules (2.64) and (2.67) to aldehyde products (2.63) and (2.66), 
followed by an end game oxidation and global deprotection would yield target molecules (-)-
(α)-kainic acid (1.1) and (-)-domoic acid (1.3). 
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Scheme 2.24: Retrosynthetic Analysis 5 
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2.3.2 The Ene-Reaction and Microwave Chemistry 
2.3.2.1 History of the Ene-Reaction 
 The ene-reaction was first identified by Alder in 1943
106
. Since then it has received a 
great deal of interest with respect to a large variety of substrates
107-109
 and moreover in the 
synthesis of a number of natural products including kainic acid (1.1)
17,34,35,37,40
. The 
intramolecular version of this concerted 6-electron pericyclic reaction occurs between an allylic 
hydrogen (ene) and electron deficient -bond (enophile). Ene-reactions are renowned for having 
higher activation energies than the related Diels-Alder cyclisation and thus higher reaction 
temperatures are generally required. These harsh conditions and long reaction times saw some 
major pitfalls in the past such as unwanted by-products and the use of high boiling solvents or 
high pressures. These factors thus hindered the widespread use of the ene-reaction in organic 
synthesis
109
. Conveniently microwave irradiation has grown in popularity in recent years as a far 
more efficient way of heating
110-112
; this has reduced the need for such elevated reaction 
temperatures and in some cases completely removed the need for solvent.  
 
2.3.2.2 The Ene-Reaction of Oxazolidinone (2.1) 
 An extensive investigation was undertaken with respect to the diastereoselective 
cyclisation of ene-precursor (2.1) (Tables 2.4-2.6). With the oxazolidinone ring installed, 
precursor (2.1) could be converted into a mixture of both the desired cis-product (2.65) and 
unwanted trans-product (2.69) in good yields and reasonable selectivity (Scheme 2.25). It was 
hoped at this stage that the undesired trans-product could be removed in the crystallisation 
process of both target molecules (1.1) and (1.3) at the end of the synthesis so, from here on the 
compounds have been treated as if they were purely of cis-stereochemistry. 
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Reagents and Conditions: i. See Tables (2.4-2.6). 
Scheme 2.25: Ene-Reaction Major Products 
 
 Oppolzer and Thirring’s reaction conditions were chosen as a starting point17 (Table 
2.4). Unfortunately after 24 hours at 130°C in toluene, no reaction had occurred (entry 1) so the 
i) 
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temperature was increased to 180°C in toluene but after 48 hours only 25% of the starting 
material had been converted and a product distribution of only 3:1 in favour of diastereoisomer 
(2.65) was seen by 
1
H-NMR analysis (entry 2). The ene-reaction proceeded in p-xylene with a 
comparatively good ratio of cis to trans-products; however the reaction times were not suitable 
(entry 3). After attempting the cyclisation in DMF and receiving disappointing results (entry 4), 
solvent free options were explored. On a small scale (<101mg) the reaction progressed at 
various temperatures however the yields and selectivity were both unsatisfactory (entries 5-9). It 
was also found that this protocol was not scaleable and simply led to molecular decomposition 
in the microwave’s heating time (entry 10).  
 
Entry Solvent Temp (°C) Scale/Conc. Time Combined yield Ratio 
(2.65:2.69) 
1 Toluene 130 5% 24 h No Reaction N/A 
2 Toluene 180 5% 48 h Trace 3:1 
3 
p
Xylene 170 1 g in 20 mL 65 h 62 5:1 
4 DMF 180 100 mg in 2 mL 1.5 h 50 3:1 
5 Neat 120 302 mg 1 h No Reaction N/A 
6 Neat 150 302 mg 20 h 30 3:2 
7 Neat 200 100 mg 56 m 55 4:1 
8 
9 
10 
Neat 
Neat 
Neat 
250 
300 
300 
100 mg 
100 mg 
>600 mg 
2 m 
1 m 
30 s 
48 
30 
Decomp. 
3:1 
4:1 
N/A 
Table 2.4: Investigation of Microwave-Induced Ene-Reaction Entries 1-10 
 
 In the laboratory N,N-diethylaniline had been found to be a reliable high boiling solvent 
for another series of microwave reactions and that removal was easily performed through 
column chromatography on silica following the reaction. This choice of solvent was discovered 
to be exceptional as long as the substrate was not too concentrated (Table 2.5). Higher 
concentrations and longer reaction times seemed to cause the cis-product to decompose at a 
greater rate from that of the trans-product and so yield and the diastereomeric ratio decreased if 
time and temperature were not controlled. It was found that by increasing the reaction 
temperature to around 200°C in DEA and increasing the reaction time to around 4 hours gave an 
optimal return and highest selectivity towards the desired target (2.65) (entry 12). It must be 
noted that used caps on the microwave vessel were not suitable for high temperature reactions. 
This observation is possibly due to not forming a tight seal and therefore not being able to hold 
the pressure as efficiently as new seals. When use of old seals cannot be avoided reaction times 
must be increased appropriately. It was pleasing to find that even at a reduced temperature and 
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longer reaction time in the microwave, selectivity decreased only marginally but in fact 
produced a better yield of products (2.65 and 2.69) (entry 13). The highest temperature of 
reaction in DEA shown (entry 11) was only attainable when using the smaller 15 mL 
microwave vials. This elevated temperature could not be reached when using the larger volume 
35 mL vials. This reaction was thereafter performed in 1 gram batches in 20 mL of DEA heated 
to 200 degrees Celsius for four hours. The crude reaction mixtures were combined and 
collectively columned.  
 
Entry Solvent Temp (°C) Scale/Conc. Time Combined yield Ratio 
(2.65:2.69) 
11 DEA 242 500 mg in 10mL 2 h 78 5:1 
12 DEA 200 1 g in 20 mL 4 h 80 7:1 
13 DEA 190 1 g in 20 mL 4.5 h 86 6:1 
14 DEA/MeCN 259 500 mg in 2.5 mL 2 h 49 3:1 
Table 2.5: Investigation of Microwave–Induced Ene-Reaction Entries 11-14 
 
 A selection of Lewis acid catalysts including tin, gold and diethylaluminium chlorides 
were also examined however the addition of these compounds did not assist in decreasing the 
activation barrier to this reaction and no products were found (entries 15-17). 
 
Entry Solvent Temp 
(°C) 
Scale/Conc. Catalyst Time Combined 
yield 
Ratio 
(2.65:2.69) 
15 CH2Cl2 -78-rt 100 mg in 10mL SnCl4 16 h No Reaction N/A 
16 CH2Cl2 Rt 100 mg in 10 mL AuCl3 48 h No Reaction N/A 
17 CH2Cl2 0-rt 100 mg in 10 mL Et2AlCl 24 h No Reaction N/A 
Table 2.6: Investigation of Ene-Reaction Entries 15-17 
 
2.3.3 The Cross Metathesis Reaction 
2.3.3.1 History and Literature Precedents for Cross Couplings 
Olefin metathesis is one of the most important carbon-carbon bond forming tools used 
in organic synthesis. In 2005 the Nobel Prize
113
 was given for the pioneering work of Chauvin, 
Grubbs and Schrock who provided both the mechanism
114
 and a variety of ruthenium
115-118
 and 
molybdenum
119,120
 based catalysts suited for the methathesis of a wide range of substituted 
olefins. Intense research in this area has provided a general model for predicting the selectivity 
and stereoselectivity of product formation in olefin cross metathesis (CM) based on the olefins 
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reactivity. These reactivities are dependant on the molecules propensity to homodimerise and 
are classed as shown (Figure 2.9)
121
. 
 
                               Type I Rapid homodimerisation, homodimers consumable 
                               Type II Slow homodimerisation, homodimers sparingly consumable 
                               Type III No Homodimerisation 
 
Reactions between two olefins of Type I = Statistical CM 
Reactions between two olefins of the same type (non Type I) = Non-selective CM 
Reactions between olefins of two different types = Selective 
Figure 2.9: Olefin Classes and Selectivity Rules121 
 
Based on these precedents two readily available Type I alkenes; isoprene (2.70) and 
ethyl acrylate (2.71) (Figure 2.10) were chosen as partners to be reacted with the Type III 
metathesis precursor (2.65). 
CO2Et
(2.70) (2.71)  
Figure 2.10: Type I Olefins 
2.3.3.2 Investigation into Metathesis of Isoprenyl group 
 A brief model study utilising the selection of readily available unsaturated molecules 
was conducted to examine the general feasibility of this approach (Scheme 2.26). The 
metathesis precursor (2.65) was first subjected to 10 mol % of Grubbs’ 1st generation catalyst 
(2.72)
115,118
 in an excess of isoprene (2.70) at room temperature. These were found to be 
inadequate conditions for the formation of cross-metathesis product (2.73), so the more robust 
Grubbs’ 2nd generation catalyst (2.74)116,117 was tested and this produced a similar result. 
Despite increased catalyst loading and heating to reflux in dichloromethane, only starting 
material (2.65) was recovered. Isoprene was substituted for ethyl acrylate (2.71) and on 
treatment with Grubbs II under reflux conditions in dichloromethane was found also to be 
ineffective at allowing conversion to the predicted product (2.73). Due to limited time a 
thorough investigation into the metathesis of the isoprenyl group has yet to be completed. 
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Reagents and Conditions: i. Grubbs I (2.57) or Grubbs II (2.59), isoprene (2.70) CH2Cl2, Δ, 6 h (no 
reaction), ii. Grubbs II (2.59), ethyl acrylate (2.71), CH2Cl2, Δ, 16 h (no reaction). 
Scheme 2.26: Investigation of Cross-Metathesis  
 
2.3.4 Final Manipulations to (-)-(α)-Kainic Acid (1.1) 
 A concurrent trans-esterification, ring-opening and N-carbamate protection was 
achieved in one-pot with a catalytic amount of caesium carbonate in methanol
122
 to furnish 
alcohol (2.64) in 80% yield (Scheme 2.27). Alcohol (2.64) was then converted into aldehyde 
(2.63) in good yield (82%) through the use of a Parikh-Doering oxidation
123
. A similar partial 
oxidation was attempted with Fetizon’s reagent (silver carbonate on Celite®) but no reaction 
occurred
124
. The synthesis was completed using a second oxidation with sodium chlorite to 
introduce the C-2 carboxyl group
125
, a subsequent deprotection of the crude acid with sodium 
hydroxide and final  purification using ion-exchange chromatography
17
 constructed the final 
target molecule (-)-(α)-kainic acid (1.1) in 60 % yield from the aldehyde (2.63). All of the data 
collected for this molecule matches that previously published
63
. The crystal structure as 
determined by x-ray crystallography is included as proof (Figure 2.11). 
 
 
 
i) 
ii) 
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Reagents and Conditions: i. Cs2CO3, MeOH, rt, 5 d (80%), ii. py.SO3, Et3N, DMSO, CH2Cl2, 0°C-rt, 16 h 
(89%), iii. 1) NaClO2, NaH2PO4, 2-methyl-2-butene, 
t
BuOH, H2O, rt, 16 h, 2) NaOH(aq), MeOH, Δ, 18 h, 
3) Ion-exchange chromatography (60% from aldehyde). 
Scheme 2.27: Final Manipulations to (-)-(α)-Kainic Acid (1.1) 
 
 
Figure 2.11: X-ray Structure of (-)-(α)-Kainic Acid (1.1) 
 
 
ii) iii) i) 
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2.4 Conclusion 
 The usefulness of oxazolidinone (2.1) as a key precursor for the synthesis of 
biologically important molecules has been demonstrated in a new highly stereoselective total 
synthesis of (-)-α-kainic acid (1.1). Two new stereocentres have been created with complete 
control in an eight step synthesis from D-serine (2.55) (Scheme 2.28). A total of three dead-
ends and one detour were explored before a viable and economical access to the valuable target 
molecule (1.1) was found. The final route gave kainic acid (1.1) in an overall yield of 20%; 
some of the intermediates yields could still be improved. Huang et al. has reported a 
quantitative conversion of D-serine (2.55) to the methyl ester (2.62)
126
 and the addition of heat 
to the ring opening of ene-product (2.65) may allow for a faster reaction times and an 
improvement in yield. Finally a number of different oxidations for the conversion of alcohol 
(2.64) to aldehyde (2.63) should also be trialed. 
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Reagents and Conditions: i. CH3COCl, MeOH, Δ, 3 h (89%), ii. Et3N, triphosgene, CH2Cl2, 0°C-rt, 24 h 
(quantitative),  iii. NaH THF:DMF (4:1 v/v), 1-bromo-3-methyl-2-butene, 0°C-rt, 16 h (78%), iv. a) 
DIBAL-H, CH2Cl2, -78°C b) NH4Cl, (C6H5)3P=CHCO2CH3, -78°C-rt, 18 h (83%). v. DEA, 200°C, 4 h 
(80%)  vi. Cs2CO3, MeOH, rt, 5 d (80%), vii. py.SO3, Et3N, DMSO, CH2Cl2, 0°C-rt, 16 h (89%), viii. 1) 
NaClO2, NaH2PO4, 2-methyl-2-butene, 
t
BuOH, H2O, rt, 16 h, 2) NaOH(aq), MeOH, Δ, 18 h, 3) Ion-              
exchange chromatography (60% from aldehyde). 
Scheme 2.28: Final Route to Kainic Acid (1.1) 
 
i) ii) 
iii) 
iv) v) 
vi) 
vii) viii) 
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 Neither introduction of the octadiene sidechain found in (-)-domoic acid (1.3) or novel 
sidechains have been realised as attempts to cross metathesise the isoprenyl unit failed to give 
any new products. It is hoped that a solution to this problem can be found by undertaking a 
more extensive investigation into the chemistry of the terminal alkene. An ozonolysis and 
sequential Wittig or Horner-Wadsworth-Emmons olefination on the resultant aldehyde (2.66) 
provides an alternative means of access to this potent alkaloid and many unknown kainates 
(Scheme 2.29). 
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Scheme 2.29: Proposed Future Route to Domoic Acid (1.3) and Novel Kainates 
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CHAPTER 3: Experimental 
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3.1 General Experimental Procedures 
 All reactions were conducted under a nitrogen atmosphere unless otherwise stated, 
using oven dried glassware. Reactions requiring anhydrous conditions were carried out using 
flame-dried glassware under nitrogen. 
 
 Analysis by thin layer chromatography was carried out using Machery Nagel glass 
backed plates pre-coated with a 0.25 mm layer of UV254 silica gel. Visualization was possible 
by ultraviolet radiation (254 nm), potassium permanganate or vanillin dips. Purification by flash 
column chromatography was carried out using Fisher Davisil
®
 60Å silica gel (particle size 35-
70 micron) or Sigma-Aldrich
®
 60Å technical grade silica gel (particle size 200-425 mesh pH 
6.5-7.5) eluting with solvents commercially available from Fisher scientific. 
 
 Melting points were recorded using a Gallenkamp melting point apparatus and are 
uncorrected. 
 
 1
H-NMR spectra were recorded using a Varian 500 instrument at 500 MHz. Samples 
were run in deuterochloroform, deutero DMSO or deuterium oxide at 30 °C and are referenced 
to a deuterochloroform, deutero DMSO or deuterium oxide internal references respectively. 
Chemical shifts are measured in ppm on the δ scale and coupling constants (J) are measured in 
Hertz. The following abbreviations were used to represent multiplicity: s, singlet; d, doublet; t, 
triplet; q, quartet; quin, quintet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublet of 
doublets; dddd, doublet of doublet, doublet, doublets; dt, doublet of triplets; td, triplet of 
doublets; br, broad; app, apparent. 
 
 13
C-NMR spectra were recorded using a Varian 500 instrument at 126 MHz. Samples 
were run in deuterochloroform, deutero DMSO or deuterium oxide, at 30 °C and are referenced 
to a deuterochloroform, deutero DMSO or deuterium oxide internal references respectively. 
Chemical shifts are measured in ppm on the δ scale. DEPT, COSY, ROESY, HSQC and HMBC 
experiments were run in conjunction with the 
13
C NMR to aid assignment. 
 
 Low and high resolution mass spectra were recorded on a Fisons Instrument VG 
Autospec mass spectrometer. The following abbreviations were used to describe the experiment: 
EI
+
, electron impact; ESI
+
, electron spray ionisation; LRMS low resolution mass spectrometry; 
HRMS, high resolution mass spectrometry. 
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 Infrared spectra were recorded on a Perkin-Elmer 1710 Fourier transform spectrometer 
with a diamond attenuated total reflectance attachment. 
 
 Microwave enhanced reactions were conducted using thick-walled glass tubes in a 
CEM Corporation® Discovery NP-1009 300W microwave system. 
 
 Chemical reagents were commercially available and used without any further 
purification unless otherwise stated. 
 
 All organic solvents were freshly distilled under a nitrogen atmosphere unless otherwise 
stated from an appropriate drying agent as described below: 
 
Solvent Drying Reagent 
 
Acetonitrile, dichloromethane, benzene, ethyl 
acetate, N,N-dimethylformamide
a
  
 
Calcium hydride 
Tetrahydrofuran, diethyl ether Sodium (in the presence of benzophenone) 
Ethanol, methanol Magnesium turnings
b 
a
 Under reduced pressure. 
b
 Magnesium turnings were first activated by heating with a crystal of iodine under a nitrogen 
atmosphere.  
 
 All compounds mentioned in the following experimental were specifically numbered to 
aid in the identification of protons and carbons in the relevant spectra. They do not necessarily 
correspond with that of the I.U.P.A.C. guidelines. 
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3.2 Compound Data 
Preparation of 3-allyl-4-vinyl-1,3-oxazolidin-2-one (2.11) and 3-allyl-5-vinyl-1,3-
oxazolidin-2-one (2.12) 
N1
2
O
3
4
5
O
(2.11) (2.12)
8
9
10
6
7
N11
12
O
14
15
O
18
19
20
16
17
 
 
These known compounds were synthesised as a mixture using a modification of the procedure 
according to Herweh et al.
75
. 
To a stirring solution of LiCl (100 mg, 2.3 mmol) in DMF (20 mL) was added 3,4-epoxy-1-
butene (2.10) (900 mg, 12.8 mmol) in 1 portion, at rt. The resulting solution was heated to 
reflux and allyl isocyanate (2.9) (1.06 mL, 12 mmol) was added dropwise. The resulting 
solution held at reflux for 6 h, after this time water (40 mL) was added and the organic 
components extracted using diethyl ether (3 x 20 mL). The solution was then dried, (MgSO4) 
concentrated under reduced pressure and purified via flash chromatography eluting with 
hexanes/diethyl ether (1:1) to afford an inseparable mixture of the title compounds (2.11) and 
(2.12) in a (1:2.5 ratio) respectively (1.1 g, 60 %) as a yellow liquid. 
 
1
H NMR (500 MHz, CDCl3) δ 5.89-5.79 (m, 2.5H, H19), 5.75 – 5.67 (m, 3.5H, H7/H17), 5.66 – 5.58 (m, 
1H, H6), 5.41 – 5.07 (m, 14H, H7/H9/H10/H16/H17/H20), 4.91 – 4.82 (m, 2.5H, H14), 4.37 (dd, J = 8.5, 
8.5 Hz, 1H, H4), 4.19 (dt, J = 8.5, 8.5 Hz, 1H, H5), 4.07 – 4.00 (m, 1H, H8), 3.95 – 3.86 (m, 1H, H4), 
3.86 – 3.72 (m, 5H, H18), 3.64 – 3.57 (m, 2.5H, H14), 3.46 (app. dt, J = 15.5, 7.5 Hz, 1H, H8), 3.18 (dd, 
J = 8.5, 8.5 Hz, 2.5H, H14). 
13
C NMR (126 MHz, CDCl3) δ 157.7(C12), 157.5 (C2), 134.5 (C19), 134.5 (C6), 131.9 (C17), 131.7 
(C9), 121.2 (C7), 121.2 (C16), 118.6 (C20), 118.5 (C10), 73.7 (C14), 67.1 (4), 58.5 (C5), 49.5 (C15), 
46.8 (C18), 44.4 (C18). 
vmax (FTIR)cm
-1
: 2983 (C-H), 1741 (C=O), 1711 (C=C), 1415, 1248 (C-N). 
HRMS (ESI
+
): calcd for C8H11O2NNa, m/z = 176.0682, found 176.0686. 
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Preparation of 4-vinyl-1,3-oxazolidin-2-one (2.14) 
 
HN1
2
O
3
4
5
O
6
7
(2.14)  
 
This known compound was synthesised using a modification of the procedure according to 
Herweh et al.
75
. 
To a stirring solution of 3,4-epoxy-1-butene (2.10) (522 mg, 7.5 mmol) in CH2Cl2 (20 mL) at rt 
was added dropwise chlorosulfonyl isocyanate (2.13) (1 g, 7.1 mmol). The resulting solution 
was left to stir for 6 h. After this time saturated KI(aq) solution (15 mL) was added and the 
organic components separated and washed with a saturated solution of saturated NH4Cl(aq) (20 
mL) then water (20 mL). The solution was then dried, (MgSO4) concentrated under reduced 
pressure and purified via flash chromatography eluting with hexanes/diethyl ether (1:4) to afford 
the title compound (2.14) (411 mg, 51 %) as a brown liquid.  
 
1
H NMR (500 MHz, CDCl3) δ 5.89 (app. ddd, J = 17.2, 10.4, 6.9 Hz, 1H, H6), 5.49 (d, J = 17.1 Hz, 1H, 
H7cis), 5.42 (d, J = 10.4 Hz, 1H, H7trans), 5.11 (app. q, J = 7.5 Hz, 1H, H4), 4.58 (app. t, J = 8.3 Hz, 1H, 
H5), 4.14 (dd, J = 7.5, 16.0 Hz, 1H, H5). 
13
C NMR (126 MHz, CDCl3) δ 154.7 (C2), 132.2 (C6), 121.1 (C7), 77.3 (C4), 69.1 (C5). 
vmax (FTIR)cm
-1
: 3576 (N-H), 2991 (C-H), 2922 (C-H), 1781(C=O), 1160 (C-O), 1052 (C-N). 
LRMS (EI
+
): m/z = 114 (34%) (Deuterated Form), 97 (18%), 69 (20%), 55 (24%), 54 (100%). 
Rf = 0.21 (1:1 diethyl ether : hexanes). 
 
Preparation of 1-isocyanato-3-methyl-2-butene (2.4) 
 
(2.4)
7
2
8
4
5
OCN 6
 
 
This known compound was synthesised using a modification of the procedure according to 
Chrisophersen et al.
72
. 
To a stirring suspension of silver cyanate (10 g, 67 mmol) in diethyl ether (35 mL) at rt in a 
darkened flask was added dropwise 1-bromo-3-methyl-2-butene (2.8) (10 g, 67 mmol). The 
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resulting solution was left stirring 2 h. After this time the solution was filtered through Celite
®
 
(500 fine) concentrated under reduced pressure and distilled (118 °C @ 20 mbar) to afford the 
title compound (2.4) (3.83 g, 51 %) as a colourless liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 5.31 (t, J = 7.0 Hz, 1H, H5), 3.82 (d, J = 7.0 Hz, 2H, H4), 1.75 (s, 3H, 
H7), 1.68 (s, 3H, H8). 
13
C NMR (126 MHz, CDCl3): δ 136.9 (C2), 120.1 (C5), 40.5 (C4), 30.5 (C6), 25.4 (C7), 17.7 (C8). 
vmax (FTIR)cm
-1
: 2976 (C-H), 2254 (N=C=O). 
LRMS (EI
+
): m/z = 111 (35%), 97 (53%), 95 (43%), 85 (44%), 84 (38%), 83 (55%), 81 (55%), 71 (55%), 
69 (100%), 57 (78%), 55 (60%).  
 
Preparation of methyl (2Z)-3-oxiran-2-ylacrylate and methyl (2E)-3-oxiran-2-ylacrylate 
(2.16) 
 
(2.16)
1
2
3
4
CO2Me5
O
6
14
10
11
12
O
9 CO2Me
13
8
16
 
 
These known compounds were synthesised as a mixture using a modification of the procedure 
according to Font et al.
71
. 
To a stirring solution of H2O2(aq) (35 wt.%) (16.5 g, 170 mmol) in water (60 mL) adjusted to pH 
8.0 by addition of a few drops 1M NaOH(aq) at rt was added dropwise acrolein (2.7) (10.1 g, 170 
mmol) whilst keeping temperature between 25-35 ºC and maintaining a pH of 8.0-8.5 through 
slow addition of 1M NaOH(aq). After 1 h at rt, (pH 8.0-8.5) the crude mixture was added 
dropwise to a stirring suspension of (triphenylphosphoranylidene) acetate (50 g, 145 mmol) in 
MeOH (215 mL) at 0 ºC. Continuous addition of 1M NaOH(aq) to dropping funnel maintained 
pH of crude epoxidation mixture. Reaction was warmed to rt and left stirring overnight. After 
this time MeOH was removed under reduced pressure and aqueous solution was extracted with 
diethyl ether (3 x 50 mL). Following repeated crystallisation and filtration of organics until no 
more triphenylphosphine oxide precipitated the residue was distilled (58 °C @ 0.5 mbar) to 
afford the title compounds (2.16) (10.6 g, 46 %) as a colourless liquid in a 1:2 ratio of cis:trans 
stereoisomers. 
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1
H NMR (500 MHz, CDCl3): δ 6.65 (dd, J = 15.7, 7.3 Hz, 0.5H, H12), 6.19 (d, J = 15.7 Hz, 0.5H, H13), 
6.02 (dd, J = 11.6, 0.6 Hz, 1H, H4), 5.75 (dd, J = 11.6, 8.4 Hz, 1H, H5), 4.60 – 4.52 (m, 1H, H3), 3.77 (s, 
3H, H8), 3.76 (s, 1.5H, H16), 3.49 – 3.43 (m, 0.5H, H11), 3.11 (dd, J = 5.3, 4.5 Hz, 1H, H2), 3.06 (dd, J 
= 5.5, 4.2 Hz, 0.5H, H10), 2.72 (dd, J = 5.5, 2.3 Hz, 0.5H, H10), 2.70 (dd, J = 5.5, 2.6 Hz, 1H, H2). 
13
C NMR (126 MHz, CDCl3): δ 166.2 (C6), 165.9 (C14), 146.9 (C5), 145.0 (C13), 123.8 (C12), 123.7 
(C4), 51.7 (C16), 51.5 (C8), 50.2 (C11), 49.2 (C3), 48.1 (C2), 48.0 (C10). 
vmax (FTIR)cm
-1
: 2997 (C-H), 2955 (C-H), 1717 (C=O), 1647 (C=C), 1440 (C-H), 1200 (C-0), 1180 (C-
Oester). 
HRMS: calcd for C6H8O3Na, m/z = 151.0351, found 151.0365. 
 
Preparation of methyl 3-chloro-3-[3-(3-methylbut-2-en-1-yl)-2-oxo-1,3-oxazolidin-5-yl] 
propanoate (2.18) 
N1
2
O
3
4
5
6
7
CO2Me
8
O
(2.18)
Cl
11
12
14
15
13
10
 
 
This unknown compound was synthesised using a modification of the procedure according to 
Herweh et al.
75
. 
To a stirring solution of epoxide (2.16) (551 mg, 4.3 mmol) in DMF (10 mL) was added CaCl2 
(150 mg, 1.4 mmol) in 1 portion, at rt. The resulting solution was placed in a silicon oil bath at 
160 ºC and once all solid had dissolved 3,3-dimethylallyl isocyanate (2.4) was added dropwise. 
The resulting solution was held at reflux for 6 h, after this time the reaction was cooled and 
water (50 mL) was added. The organic components were extracted using diethyl ether (3 x 30 
mL) washed with saturated NaCl(aq) (1 x 25 mL) then dried, (MgSO4) concentrated under 
reduced pressure and purified via flash chromatography eluting with hexanes/diethyl ether (1:1) 
to afford the title compound (2.18) as single diasteromer (based on 
1
H-NMR data) (45 mg, 4 %) 
as a brown liquid.  
 
1
H NMR (500 MHz, CDCl3): δ 5.14 (t, J = 7.1 Hz, 1H, H12), 4.5 (app. q, J = 4.0 Hz, 1H, H4), 4.06 (dd, J 
= 6.2, 15.5 Hz, 1H, H11), 3.96 (dt, J = 8.95, 3.9 Hz,  1H, H6), 3.75 (d, J = 4.1 Hz, 2H, H5), 3.71 (s, 3H, 
H10), 3.67 (dd, J = 15.5, 7.7 Hz, 1H, H11), 2.78 (dd, J = 3.7, 16.4 Hz, 1H, H7), 2.56 (dd, J = 9.1, 16.4 
Hz, 1H, H7), 1.74 (s, 3H, H14), 1.70 (s, 3H, H15). 
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13
C NMR (126 MHz, CDCl3): δ 170.3 (C8), 156.3 (C2), 137.9 (C13), 117.7 (C12), 76.9 (C4), 54.2 (C6), 
52.0 (C10), 45.4 (C5), 40.1 (C11) 37.0 (C7), 25.6 (C14), 17.9 (C15). 
vmax (FTIR)cm
-1
: 2966 (C-H), 1731 (C=O), 1436 (C-H), 1241 (C-O), 1200 (C-Oester), 1165 (C-N), 755 (C-
Cl). 
HRMS: calcd for C12H18
35
ClNO4Na, m/z = 298.0810, found 298.0816  
 
Attempted Preparation of methyl (2E)-3-[3-(3-methylbut-2-en-1-yl)-2-oxo-1,3-oxazolidin-
5-yl]acrylate (2.19) 
N
OO
CO2Me
(2.19)  
  
We were unable to isolate a pure analytical sample of (2.19) and decomposition followed. 
 
Preparation of methyl (2E)-3-(2-oxo-1,3-oxazolidin-5-yl)acrylate (2.21) 
 
HN
1
2
O
3
4
5
6
7
CO2Me
8
O
(2.21)
10
 
 
This unknown compound was synthesised using a modification of the procedure according to 
Herweh et al.
75
. 
To a stirring solution of epoxide (2.16) (501 mg, 3.9 mmol) in CH2Cl2 (2 mL) at 0 °C was added 
dropwise chlorosulfonyl isocyanate (2.13) (553 mg, 3.9 mmol). The resulting solution was left 
to stir for 4 h. After this time saturated KI(aq) solution (20 mL) was added.  The organic 
components were extracted using CH2Cl2 (3 x 15 mL) washed with saturated NaCl(aq) (2 x 15 
mL) and water (2 x 15 mL), then dried, (MgSO4) concentrated under reduced pressure and 
purified via flash chromatography eluting with hexanes/diethyl ether (1:4) to afford the title 
compound (2.21) (110 mg, 17 %) as a brown liquid.  
 
1
H NMR (500 MHz, CDCl3): δ 6.86 (dd, J = 15.7, 5.5 Hz, 1H, H6), 6.18 (d, J = 15.7 Hz, 1H, H7), 5.30 
(app. qd, J = 7.0, 1.3 Hz, 1H, H4), 4.65 (app. t, J = 8.5 Hz, 1H, H5), 4.19 (dd, J = 8.5, 7.1 Hz, 1H, H5), 
3.75 (s, 3H, H10). 
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13
C NMR (126 MHz, CDCl3): δ 165.3 (C8), 154.1 (C2), 139.7 (C6), 124.5 (C7), 74.6 (C4), 68.5 (C5), 
52.0 (C10). 
vmax (FTIR)cm
-1
: 2957 (C-H), 1790 (C=O), 1718 (C=O), 1270 (C-N), 1159 (C-Oester), 1062 (C-Oester). 
LRMS (EI
+
): m/z = 173 (14%) (Deuterated Form), 149 (67%), 141 (100%), 128 (11%), 100 (60%), 99 
(34%), 87 (30%), 69 (37%), 59 (61%), 55 (76%), 42 (44%), 41 (99%), 38 (63%). 
 
 Preparation of isopropylidene glycerol (2.27) 
 
(2.27)
1O 23
4
O
5
6
7 8
OH
 
 
This known compound was synthesised using a modification of the procedure according to 
Newman et al.
84
. 
A mixture of glycerol (2.28) (100 g, 1.09 mol), acetone (300 mL), pentane (300 mL) and PTSA 
monohydrate (3 g, 16 mmol) was placed in a single neck 1 L flask fitted with stirrer bar and 
helices packed 14 inch column topped by a Dean-Stark apparatus and condenser. The mixture 
was stirred at reflux (temp @ head 31°C) for 35 h (Mixture was homogenous after 13.5 h). The 
reaction was cooled and neutralised with anhydrous sodium acetate (1.3 g, 16 mmol) then 
filtered. After removal of solvent the residue was distilled (80 °C 15 mbar) to afford title 
compound (2.27) (135.14 g, 95 %) as a colourless liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 4.27 – 4.21 (m, 1H, H5), 4.04 (dd, J = 8.4, 7.3 Hz, 1H, H4), 3.80 (dd,  J = 
9.5, 8.4  Hz, 1H, H4), 3.74 (dt, J = 11.4, 4.4 Hz, 1H, H6), 3.60 (dt, J = 11.4, 5.5 Hz, 1H, H6), 1.83 (s, 1H, 
OH), 1.45 (s, 3H, H7), 1.38 (s, 3H, H8). 
13
C NMR (126 MHz, CDCl3): δ 109.4 (C2), 76.1 (C5), 65.7 (C4), 63.0 (C6), 26.7 (C7), 25.0 (C8). 
vmax (FTIR)cm
-1
:  3434 (OH) 2987 (C-H), (2936 (C-H), 1047 (C-Oalcohol). 
HRMS: calcd for C6H12O3Na, m/z = 155.0679, found 155.0681. 
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Preparation of methyl (2E)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)acrylate and methyl (2Z)-3-
(2,2-dimethyl-1,3-dioxolan-4-yl)acrylate (2.30) 
 
(2.30)
1O 23
4
O
5
6 7
8
11
1O 23
4
O
5
6
7
8
11
CO2Me
10
CO2Me
10
(E) (Z)
12 12
 
 
These known compounds were synthesised using a modification of the procedure according to 
Ireland et al.
85
. 
To a stirring solution of (COCl)2 (44.57 g, 349 mmol) in CH2Cl2 (750 mL) at -78 °C was added 
dropwise DMSO (32.0 g, 411 mmol) in CH2Cl2 (20 mL) then mixture was left stirring for 20 
min before addition of alcohol (2.27) (20.93 g, 158 mmol) in CH2Cl2 (250  mL) from a dropping 
funnel. Funnel was rinsed with CH2Cl2 (10 mL) and mixture left stirring for additional 30 min. 
Et3N (110 mL, 792 mmol) was then placed in dropping funnel, added slowly and left stirring at 
-78 °C. Following 30 min, the mixture was allowed to warm to -10 °C and 
(triphenylphosphoranylidene) acetate (79.45 g, 238 mmol) in CH2Cl2 (250 mL) was added 
dropwise before allowing mixture to warm to rt and stir overnight. Following removal of 
solvent residue was subject to column chromatography eluting with 15% diethyl ether/hexanes 
to afford title compound (2.30) (21.96 g, 74 %) as a pale yellow liquid containing a mixture of 
cis/trans isomers. (E:Z =1:07) which, was carried forward to next step. 
 
E isomer 
1
H NMR (500 MHz, CDCl3): δ 6.89 (dd, J = 15.6, 5.6 Hz, 1H, H6), 6.11 (dd, J = 15.6, 1.3 Hz, 1H, H7), 
4.66 (td, J = 6.8, 6.8 Hz, 1H, H5) 4.18 (dd, J = 6.7, 8.2 Hz, 1H, H4), 3.75 (s, 3H, H10), 3.67 (dd, J = 7.2, 
8.1 Hz, 1H, H4), 1.44 (s, 3H, H11), 1.40 (s, 3H, H12). 
13
C NMR (126 MHz, CDCl3): δ 166.4 (C8), 145.0 (C6), 121.9 (C7), 110.2 (C2), 74.9 (C5), 68.8 (C4), 
51.7 (C10), 26.4 (C11), 25.7 (C12). 
vmax (FTIR)cm
-1
: 2987 (C-H), 1719 (C=O), 1438 (C-H), 1200 (C-O), 1180 (C-O), 1154(C-O), 1055. 
HRMS: calcd for C9H14O4Na, m/z = 209.0784, found 209.0786. 
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Z isomer 
1
H NMR (500 MHz, CDCl3): δ 6.37 (dd, J = 15.5, 5.6 Hz, 1H, H6), 5.86 (dd, J = 15.5, 1.3 Hz, 1H, H7), 
5.50 (td, J = 6.8, 1.2 Hz, 1H, H5), 4.38 (dd, J = 8.3, 6.7 Hz, 1H, H4), 3.72 (s, 3H, H10), 3.62 (dd, J = 8.3, 
6.7 Hz, 1H, H4), 1.45 (s, 3H, H11), 1.39 (s, 3H, H12).  
13
C NMR (126 MHz, CDCl3): δ 166.0 (C8), 149.5 (C6), 120.3 (C7), 109.7 (C2), 73.45 (C5), 69.3 (C4), 
51.5 (C10), 26.5 (C11), 25.4 (C12). 
vmax (FTIR)cm
-1
: 2988 (C-H), 1721 (C=O), 1436 (C-H), 1259 (C-O), 1211 (C-O), 1154 (C-0), 1058. 
HRMS: calcd for C9H14O4Na, m/z = 209.0784, found 209.0781. 
 
Preparation of methyl (3E)-5-hydroxy-3-pentenoate (2.25) 
 
(2.25)
HO
1
2
3
4
5
CO2Me
7
 
 
This known compound was synthesised using a modification of the procedure according to Pak 
et al.
82
. 
To a solution of (2.30) (8.1 g, 44 mmol) in MeOH (225 mL) at -23 °C stirred by a glass stirrer 
bar was added powdered magnesium (3.2 g, 130 mmol) and carborundum (1 spatula) Following 
2 h the mixture was diluted with diethyl ether (225 mL) and filtered through Celite
®
 (500 fine). 
Following removal of solvent, residue was subject to column chromatography eluting with 
hexanes/diethyl ether (1:1) to afford the title compound (2.25) (3.6 g, 64 %) as a pale yellow 
liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 5.87 – 5.80 (m, 1H, Ha), 5.80 – 5.71 (m 1H, H2), 4.15 (app. t, J = 4.7 Hz, 
2H, H1), 3.70 (s, 3H, H7), 3.11 (d, J = 6.1 Hz, 2H, H4), 1.40 (s, 1H, OH). 
13
C NMR (126 MHz, CDCl3): δ 172.1 (C5), 133.3 (C2), 123.5 (C3), 63.0 (C1), 51.8 (C7), 37.4 (C4). 
vmax (FTIR)cm
-1
: 3420 (OH), 2953 (C-H), 1733 (C=O), 1436 (C-H), 1202 (C-Oester), 1158 (C-Oester), 970 
(C-Oalcohol). 
HRMS: calcd for C6H10O3Na, m/z = 153.0522, found 153.0523. 
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Preparation of methyl 3,4-anhydro-2-depxy-D-threo-pentonate (2.24) 
 
(2.24)
HO
1
2
3
4
5
CO2Me
O 7
 
 
This known compound was synthesised using a modification of the procedure according to 
Sharpless et al.
87
. 
Ti(
i
OPr)4 (1.86 g, 9.8 mmol) was added to a stirring solution of (+)DIPT (2.29 g, 9.8 mmol) and 
powdered activated 4Å molecular sieves (2 g) in CH2Cl2 (90 mL) at -25°C. (2.25) (8.5 g, 65.3 
mmol) was added dropwise to this solution followed by dropwise addition of 5M TBHP in 
CH2Cl2 (19.6 mL 98 mmol). Reaction vessel was placed in -25°C freezer for a period of 31 
Days. Solution was warmed to 0°C and poured into a  stirring solution of ferrous sulfate 
heptahydrate (3.27 g, 11.8 mmol)  in H2O (18.6 mL). After 10 mins the organic components 
were extracted using CH2Cl2 (3 x 20 mL) combined then dried (MgSO4), concentrated under 
reduced pressure and purified via column chromatography on neutral silica eluting with 
hexanes/diethyl ether (1:1) to afford the title compound (2.24) (7.59 g, 75 % based on recovered 
SM) as a pale yellow liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 3.89 (d, J =12.8 Hz, 1H, H8), 3.71 (s, 3H, H7), 3.66 (d, J = 12.8 Hz, 1H, 
H8), 3.34 - 3.28 (m, 1H, H3), 3.07 – 2.92 (m, 1H, H2), 2.61 (d, J = 5.6 Hz, 2H, H4) 2.14 (s, 1H, OH). 
13
C NMR (126 MHz, CDCl3): δ 170.7 (C5), 61.2 (C8), 58.1 (C2), 52.0 (C7), 51.3 (C3), 37.0 (C4). 
vmax (FTIR)cm
-1
: 3450 (OH), 2925 (C-H), 1732(C=O), 1438 (C-H), 1259, 1174 (C-Oester), 1158. 
HRMS: calcd for C6H10O4Na, m/z = 169.0471, found 169.0472. 
[α]D
23
 = -21.9, (c = 1.00, MeOH). No Lit. values found. 
 
Preparation of methyl 3,4-anhydro-5-O[tert-butyl(dimethyl)silyl]-2-depxy-D-threo-
pentonate (2.31) 
(2.31)
O
1
2
3
4
5
CO2MeSi11
12
10
O
13
7
 
 
This unknown compound was synthesised using a modification of the procedure according to 
Hon et al.
88
. 
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To a stirring solution of (2.24) (235 mg, 1.6 mmol) in CH2Cl2 (2 mL) at 0 °C was added 
sequentially imidazole (273 mg, 4.0 mmol), DMAP (20 mg, 0.2 mmol) and TBSCl (363 mg, 2.4 
mmol). Following 1 h diethyl ether (10 mL) was added and the reaction quenched with H2O (10 
mL). The organic phase was separated, concentrated under reduced pressure and residue was 
subject to column chromatography eluting with hexanes/diethyl ether (3:1) to afford the title 
compound (2.31) (402 mg, 96 %) as a colourless liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 3.85 (dd, J = 12.0, 3.1 Hz, 1H, H8), 3.73 (s, 3H, H7), 3.69 (dd, J = 12.0, 
4.6 Hz, 1H, H8), 3.24 – 3.19 (m, 1H, H3), 2.95 – 2.91 (m, 1H, H2), 2.60 (d, J = 5.9 Hz, 2H, H4) 0.90 (s, 
9H, Hg), 0.07 (d, J = 3.6 Hz, 6H, Hh). 
13
C NMR (126 MHz, CDCl3): δ 170.7 (C5), 62.9 (C8), 58.4 (C2), 51.9 (C7), 51.4 (C3), 37.2 (C4) 25.8 
(C12), 18.3 (C11), -5.4 (C13). 
vmax (FTIR)cm
-1
: 2954 (C-H), 2930 (C-H), 2857 (C-H), 1744(C=O), 1472 (C-H), 1437, 1345, 1255 (Si-
CH3), 1174 (C-Oester), 1107 (Si-OR), 838 (Si-C), 779 (Si-C). 
HRMS: calcd for C12H24O4SiNa, m/z = 283.1336, found 283.1336. 
[α]D
23
 = -13.0, (c = 1.10, MeOH). 
 
Preparation of methyl 4-azido-5-O-[tert-butyl(dimethyl)silyl]-2,4-dideoxy-L-erythro-
pentonate (2.32) 
(2.32)
O
1
2 3 4
5
CO2Me6Si
12
N3
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7
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This unknown compound was synthesised using a modification of the procedure according to 
Zwanenburg et al.
89
. 
To a stirring solution of (2.31) (376 mg, 1.4 mmol) in MeOH/H2O (10:3, v/v) (3 mL) at rt was 
added sodium azide (188 mg, 2.9 mmol) and (NH4)2SO4 (229 mg, 1.7 mmol) and mixture was 
heated to reflux. After 48 h the mixture was cooled, diluted with H2O (10 mL) and diethyl ether 
(10 mL). Organic components were extracted using diethyl ether (2 x 10 mL), combined, 
washed with brine (1 x 20 mL) then dried (MgSO4), concentrated under reduced pressure and 
purified via column chromatography on neutral silica eluting with hexanes/diethyl ether (2:1) to 
afford the title compound (2.32) (144 mg, 47 %) as a yellow liquid. 
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1
H NMR (500 MHz, CDCl3): δ 4.07 – 4.01 (m, 1H, H6), 3.95 (dd, J = 10.7, 4.1 Hz, 1H, H5), 3.83 (dd, J = 
10.7, 6.6 Hz, 1H, H5), 3.74 (s, 3H, H11), 3.49 – 3.41 (m, 1H, H7), 2.68 (dd, J = 16.6, 3.2 Hz, 1H, H8) 
2.55 (dd, J = 16.6, 8.7 Hz, 1H, H8), 0.92 (s, 9H, H1), 0.11 (s, 6H, H12). 
13
C NMR (126 MHz, CDCl3): δ 172.9 (C9), 67.8 (C6), 65.7 (C7), 63.6 (C5), 51.9 (C11), 37.6 (C8) 25.7 
(C1), 18.1 (C2), -5.6 (C12). 
vmax (FTIR)cm
-1
: 3482 (OH), 2954 (C-H), 2930 (C-H), 2858 (C-H), 2100 (N3),  1744(C=O), 1464 (C-H), 
1438, 1362, 1258 (Si-CH3), 1173 (C-Oester), 1114 (Si-OR), 838 (Si-C), 779 (Si-C). 
LRMS: (ESI
+
) C12H24N3O4SiNa, found 326.1031. 
[α]D
23
 = -24.3, (c = 1.75, CH2Cl2). 
 
Preparation of methyl (2E,4S)-5-{[tert-butyl(dimethyl)silyl]oxy}-4-hydroxypent-2-enoate 
(2.34) 
 
(2.34)
O
1
2 3 4
5
CO2Me6Si
11
12
OH
97
8
 
 
This known compound was synthesised using a modification of the procedure according to 
Blum et al.
91
. 
To a stirring solution of (2.31) (3.17 g, 12.2 mmol) in acetone/H2O (1:1, v/v) (36 mL) at rt was 
added sodium azide (2.77 g, 42.6 mmol) and mixture was heated to reflux. After 56 h the 
solvent was removed under reduced pressure and residue extracted using CH2Cl2 (20 mL). The 
organic solution was washed with H2O (2 x 10 mL) then dried (Na2SO4), concentrated under 
reduced pressure and purified via column chromatography on neutral silica eluting with 
hexanes/diethyl ether (5:1) to afford the title compound (2.34) (1.61 g, 51 %) as a colourless 
liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 6.87 (dd, J = 15.8, 4.5 Hz, 1H, H7), 6.11 (d, J = 15.8 Hz, 1H, H8), 4.32 
(app. s, 1H, H6), 3.71 (s, 3H, H11), 3.70 – 3.71 (m, 1H, H5), 3.48 (dd, J = 10.0, 7.1 Hz, 1H, H5) 2.78 (Br. 
s, 1H, OH), 0.86 (s, 9H, H12), 0.05 (s, 6H, H11). 
 
13
C NMR (126 MHz, CDCl3): δ 166.7 (C9), 146.2 (C7), 121.3 (C8), 71.3 (C6), 66.2 (C5), 51.5 (C11) 25.8 
(C1), 18.2 (C2), -5.5 (C12). 
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vmax (FTIR)cm
-1
: 3456 (OH), 2954 (C-H), 2930 (C-H), 2858 (C-H), 1726 (C=O), 1255 (Si-CH3), 1104 
(Si-OR), 834 (Si-C), 776 (Si-C). 
HRMS: calcd for C12H26O3SiNa, m/z = 260.1676, found 260.1677. 
[α]D
24
 = 0.08, (c = 1.85. CH2Cl2). No Lit. values found. 
 
Preparation of methyl [(2S,3R)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)aziridin-2-
yl]acetate (2.29) 
(2.29)
O
1
2
3 4
5
CO2Me
7HN10
Si
11
12
13
 
 
This unknown compound was synthesised using a modification of the procedure according to 
Zwanenburg et al.
89
. 
To a stirring solution of (2.31) (122 mg, 0.4 mmol) in MeCN (2 mL) at RT was added 
triphenylphosphine (111 mg). After 10 mins the mixture was heated to reflux. Following 5 h the 
mixture was cooled and diluted with hexanes/diethyl ether (1:1) (4 mL) before concentrating 
under reduced pressure. The residue was subject to column chromatography eluting with 
hexanes/diethyl ether (3:2) to afford the title compound (2.29) (81 mg, 79 %) as an orange 
liquid. 
1
H NMR (500 MHz, CDCl3): δ 3.76 (d, J = 2.4 Hz, 1H,  H8), 3.65 (s, 1H, H7), 2.38 (dd, J = 16.1, 6.5 Hz, 
1H, H4), 2.42 (dd, J = 16.1, 6.2 Hz, 1H, H4), 2.18 (app. s, 1H, H3), 1.85 (app. s, 1H, H2) 0.85 (s, 9H, 
H13), 0.01 (s, 6H, H11). 
13
C NMR (126 MHz, CDCl3): δ 172.0 (C5), 61.2 (C8), 51.6 (C7), 38.0 (C4), 37.51 (C2), 28.7 (C3) 25.8 
(C13), 18.2 (C12), -5.5 (C11). 
vmax (FTIR)cm
-1
: 2954 (C-H), 2930 (C-H), 2858 (C-H), 1739 (C=O), 1252 (Si-CH3), 1097 (Si-OR), 834 
(Si-C), 776 (Si-C). 
HRMS: calcd for C12H24O4SiNa, m/z = 283.1336, found 283.1341. 
 
Preparation of (but-3-yn-1-yloxy)(triisopropyl)silane (2.40) 
 
(2.40)
1
2
3
4
O
Si(iPr)25
6
8
7
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This known compound was synthesised using a modification of the procedure according to 
Razon et al.
93
. 
To a stirring solution of 3-butyn-1-ol (2.41) (10.0 g, 143 mmol) and Et3N (21.7 g, 214 mmol) in 
CH2Cl2 (150 mL) at 0 °C was added dropwise TIPSOTf (45.9 g, 149 mmol). Following 18 h the 
reaction mixture was washed with saturated NaHCO3(aq) (2 x 150 mL). Organics separated, dried 
(Na2SO4) and concentrated under reduced pressure. The residue was passed through a silica 
plug eluting with hexanes/diethyl ether (95:5) to afford the title compound (2.40) (32.1 g, 99 %) 
as a colourless liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 3.80 (t, J = 7.3 Hz, 2H, H4), 2.43 (td, J = 14.6, 7.3, 2.6 Hz, 2H, H3), 1.94 
(t, J = 2.6 Hz, 1H, H1), 1.11 – 1.03 (m, 21H, H7/H8). 
13
C NMR (126 MHz, CDCl3): δ 81.4 (C2), 69.2 (C1), 62.0 (C4), 22.9 (C3), 17.9 (C8), 12.0 (C7). 
vmax (FTIR)cm
-1
: 3315 (C-HAlkyne), 2944 (C-H), 2867 (C-H), 1463, 1114.  
HRMS: calcd for C13H26OSiNa, m/z = 249.1645, found 249.1646. 
 
Preparation of 5-[(triisopropylsilyl)oxy]pent-2-yn-1-ol (2.39) 
 
(2.39)
2
3
HO
1
4
5
6
O
Si(iPr)27
8
10
9
 
 
This known compound was synthesised using a modification of the procedure according to 
Razon et al.
93
. 
To a stirring solution of (2.40) (10.0 g, 44.2 mmol) in THF (110 mL) at -78 °C was added 
dropwise 
n
BuLi(2.5M) (22.96 mL, 57.4 mmol) Following 25 mins, paraformaldehyde (1.5 g, 
48.6 mmol) was added in one portion and mixture left stirring for 6 h. Reaction quenched with 
H2O (100 mL). Organics separated and aqueous phase extracted with diethylether (3 x 50 mL) 
and organic phases combined, dried (Na2SO4) and concentrated under reduced pressure. Residue 
was subject to column chromatography eluting with hexanes/diethyl ether (93:7 – 85:15) to 
afford the title compound (2.39) (9.78 g, 92 %) as a colourless liquid. 
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1
H NMR (500 MHz, CDCl3): δ 4.22 (s, 1H, H2), 3.79 (t, J = 7.5 Hz, 1H, H5), 2.45 (t, J = 7.3 Hz, 1H, 
H6), 1.73 (s, 1H, OH), 1.11 – 1.03 (m, 21H, H9/H10). 
13
C NMR (126 MHz, CDCl3): δ 83.1 (C4), 79.5 (C3), 62.1 (C5), 51.0 (C2), 23.1 (C6), 17.9 (C9), 11.9 
(C10). 
vmax (FTIR)cm
-1
: 3336 (O-H), 2942 (C-H), 2866 (C-H), 1463, 1107.  
HRMS: calcd for C14H28O2SiNa, m/z = 279.1751, found 279.1747. 
 
 
Preparation of (2E)-5-[(triisopropylsilyl)oxy]pent-2-en-1-ol (2.38) 
 
(2.38)
HO
1
2
3
4
5
6
O
7
Si(iPr)2
9
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8
 
 
This known compound was synthesised using a modification of the procedure according to 
Razon et al.
93
. 
(2.39) was added dropwise to a stirring solution of LAH (3.01 g, 80.5 mmol) in THF (250 mL) 
at -10 °C The mixture was warmed to RT and left overnight. The mixture was cooled to -5 °C 
and cautiously quenched with 5% NaOH(aq) (200 mL). H2O (200 mL) was added and the phases 
separated. Aqueous phase was extracted with diethylether (3 x 200 mL) and and organic phases 
combined, dried (Na2SO4) and concentrated under reduced pressure. Residue was subject to 
column chromatography eluting with hexanes/diethyl ether (4:1) to afford the title compound 
(2.38) (19.41 g, 98 %) as a colourless liquid. 
 
1
H NMR (500 MHz, CDCl3): δ 5.71 (m, 1H, H4), 5.70 (m, 1H, H3), 4.07 (d, J = 4.1 Hz, 2H, H2), 3.70 (t, 
J = 6.7 Hz, 2H, H6), 2.31 (app. t, J = 6.7 Hz, 2H, H5), 1.48 (s, 1H, OH), 1.09 – 1.02 (m, 21H, H9/H10). 
13
C NMR (126 MHz, CDCl3): δ 130.8 (C3), 129.6 (C4), 63.7 (C2), 63.0 (C6), 36.0 (C5), 18.0 (C9), 12.0 
(C10). 
vmax (FTIR)cm
-1
: 3337 (O-H), 2943 (C-H), 2866 (C-H), 1463, 1105. 
HRMS: calcd for C14H30O2SiNa, m/z = 281.1907, found 281.1904. 
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Preparation of 3,4-anhydro-2-deoxy-1-O-(triisopropylsilyl)-L-threo-pentitol (2.37)  
 
(2.37)
HO
1
2
3
4
5
6
O
7
Si(iPr)2
9
10
O
8
 
 
This novel compound was synthesised using a modification of the procedure according to 
Sharpless et al.
87
. 
Ti(
i
OPr)4 (2.09 g, 7.35 mmol) was added to a stirring solution of (+)DIPT (2.58 g, 11.0 mmol) 
and powdered activated 4Å molecular sieves (3.0 g) in CH2Cl2 (100 mL) at -25 °C. (2.38) 
(19.01 g, 73.5 mmol) was added dropwise to this solution followed by dropwise addition of 5M 
TBHP in CH2Cl2 (22 mL, 110 mmol). Reaction vessel was placed in -25 °C freezer overnight. 
Solution was warmed to 0 °C and quenched with 40 mL of water. After stirring for an additional 
hour 30% NaOH saturated with NaCl in water (9.5 mL) was added and mixture stirred 
vigorously for 30 mins before filtering through glass paper and separation of organic phase. The 
organic components were extracted using CH2Cl2 (3 x 100 mL) combined then dried (Na2SO4), 
concentrated under reduced pressure and purified via column chromatography on neutral silica 
eluting with hexanes/diethyl ether (2:1) to afford the title compound (2.37) (13.56 g, 67 %) as a 
colourless oil.  
 
General Preparation and Analysis of Moshers Esters. 
 DMAP (18 mg 0.15 mmol) Et3N (100 µL) were dissolved in stirring CH2Cl2 (0.5 mL) The 
epoxide (either neat or as an aliquot of a crude epoxidation reaction mixture) was added and 
immediately, (+)-a-methoxy-a-(trifluoromethy1)phenylacetyl chloride (MTPA chloride) (30 
µL) was added. The solution became warm and turned orange. Following 5 min reactions were 
quenched by addition of 3-(dimethylamino)propylamine (40-60 µL) and concentrated, and the 
residue was passed through a short plug of silica gel in order to remove polar impurities (20% 
EtOAc/hexane).  
 
1
H NMR (500 MHz, CDCl3): δ 3.91 (ddd, J = 12.5, 5.6, 2.4 Hz, 1H, H2), 3.83 (t, J = 6.2 Hz, 2H, H6), 
3.66 – 3.56 (ddd, J = 12.0, 7.2, 4.7 Hz, 1H, H2), 3.11 (td, J = 5.9, 2.3 Hz, 1H, H4), 2.98 (dt, J = 4.6, 2.4 
Hz, 1H, H3), 1.90 (t, J = 6.3 Hz, 1H,  OH), 1.85 – 1.72 (m, 2H, H5), 1.14 – 0.98 (m, 21H, H9/H10). 
 
13
C NMR (126 MHz, CDCl3): δ 61.8 (C2), 60.1 (C6), 58.6 (C3), 53.8 (C4), 35.1 (C5), 18.0 (C9), 11.9 
(C10). 
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vmax (FTIR)cm
-1
: 3435 (O-H), 2944 (C-H), 2867 (C-H), 1464, 1107.  
HRMS: calcd for C14H30O3SiNa, m/z = 297.1856, found 297.1858. 
[α]D
24
 = -27.1 (c = 1.70, CH2Cl2). 
Enantiomeric excess  = 64%. See Appendix for 
1
H-NMR spectra of Moshers esters. 
 
Preparation of 3,4-anhydro-2-deoxy-5-O-(triethylsilyl)-1-O-(triisopropylsilyl)-L-threo-
pentitol (2.43)  
(2.43)
(Et)2
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This novel compound was synthesised using a modification of the procedure according to Corey 
et al.
92
.  
To a stirring solution of (2.37) (200 g, 72.3 mmol) and imidazole (14.86 g, 218.6 mmol) in 
CH2Cl2 (275 mL) at rt was added dropwise TESCl (13.88 g, 87.4 mmol). Following 1 h, 
reaction quenched with brine (150 mL). The organics were extracted with CH2Cl2 (3 x 150 mL), 
combined, dried (Na2SO4) and concentrated under reduced pressure. The residue was subject to 
column chromatography eluting with hexanes/diethyl ether (98:2) to afford the title compound 
(2.43) (27.44 g, 97 %) as a colourless oil. 
 
1
H NMR (500 MHz, CDCl3): δ 3.86 – 3.83 (m, 2H, H9), 3.83 – 3.81 (m, 1H, H5), 3.67 – 3.61 (dd, J = 
11.8,  4.9 Hz, 1H, H5), 3.01 (m, 1H, H7), 2.91 (m, 1H, H6), 1.92 – 1.78 (m, 1H, H8), 1.78 – 1.67 (m, 1H, 
H8), 1.16 – 1.00 (m, 21H, H12/H13), 0.96 (t, J = 8.0 Hz, 9H, H1i), 0.62 (q, J = 8.0 Hz, 6H, H2). 
 
13
C NMR (126 MHz, CDCl3): δ 63.3 (C5), 60.2 (C9), 58.8 (C6), 53.8 (C7), 35.4 (C8), 17.9 (C12), 11.9 
(C13), 6.6 (C1), 4.4 (C2). 
 
vmax (FTIR)cm
-1
: 2943 (C-H), 2867 (C-H), 1462, 1100 (C-O). 
HRMS: calcd for C20H44O3Si2Na, m/z = 411.2721, found 411.2719. 
[α]D
24
 = -10.1 (c = 1.10, CH2Cl2).  
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Preparation of 3,4-anhydro-2-deoxy-5-O-(ethoxycarbonyl)-1-O-(triisopropylsilyl)-L-threo-
pentitol (2.44)  
(2.44)
4 O
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This novel compound was synthesised using a modification of the procedure according to Guo 
et al.
96
. 
To a stirring solution of (2.37) (1.0 g, 3.65 mmol), DMAP (76 mg, 0.62 mmol) and pyridine 
(1.15 g, 14.6 mmol) in CH2Cl2 (8 mL) at 0 °C was added dropwise ethyl chloroformate (1.58 g, 
14.6 mmol). After 3 h a precipitate formed and saturated CuSO4(aq)  (30 mL) was added. The 
aqueous mixture was extracted with diethyl ether (3 x 30 mL), the organic layers were 
combined, dried (Na2SO4) and concentrated under reduced pressure. The residue was subject to 
column chromatography eluting with hexanes/diethyl ether (9:1) to afford the title compound 
(2.44) (1.2 g, 95 %) as a yellow liquid. 
1
H NMR (500 MHz, CDCl3): δ 4.36 (dd, J = 12.0, 3.2 Hz, 1H, H6), 4.20 (q, J = 7.1 Hz, 2H, H2), 4.04 
(dd, J = 12.0, 6.0 Hz, 1H,  H6), 3.83 (t, J = 6.2 Hz, 2H, H10), 3.07 – 3.04 (m, 1H, H7), 3.04 – 3.01 (m, 
1H, H8), 1.88 – 1.79 (m, 1H, H9), 1.79 – 1.70 (m, 1H, H9), 1.30 (t, J = 7.3 Hz, 3H, H1,) 1.13 – 1.00 (m, 
42H, H13/H14) 
13
C NMR (126 MHz, CDCl3): δ 154.9 (C4), 67.8 (C6), 64.2 (C2), 60.0 (C10), 55.1 (C7), 54.2 (C8), 35.1 
(C9), 17.9 (C14), 14.2 (C1), 11.9 (C13). 
vmax (FTIR)cm
-1
: 2944 (C-H), 2867 (C-H), 1748 (C-O), 1464, 1250 (C-O). 
HRMS: calcd for C17H34O5SiNa, m/z = 369.2068, found 369.2072. 
[α]D
24
 = -24.6 (c = 1.80, CH2Cl2). 
 
Preparation of 3,4-anhydro-2-deoxy-5-O-(tetrahydro-2H-pyran-2-yl)-1-O-
(triisopropylsilyl)-L-threo-pentitol (2.45)  
 
(2.45)
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This novel compound was synthesised using a modification of the procedure according to 
Miyashita et al.
97
. 
To a stirring solution of (2.37) (13.25 g, 48.3 mmol), and DHP (6.09 g, 72.4 mmol) in CH2Cl2 
(350 mL) at rt was added PPTS (1.15 g, 4.8 mmol). After 36 h diethyl ether (150 mL) and 50% 
brine(aq) (300 mL) was added. The organic phase was separated and organics extracted with 
CH2Cl2 (100 mL), combined, dried (Na2SO4) and concentrated under reduced pressure. The 
residue was subject to column chromatography eluting with hexanes/diethyl ether (4:1) to afford 
the title compound (2.45) (16.10 g, 93 %) as a yellow oil consisting of a mixture of 
diastereomers. 
 
1
H NMR and 
13
C NMR values have been characterised by arbitrary assignment of peaks 
due to recognition of diastereomers caused by the chirality of THP group. Compounds 
confirmed by associated Mass and IR data.  
1
H NMR (500 MHz, CDCl3): δ 4.70 – 4.57 (m, 2H, H6), 3.95 – 3.89 (m, 1H, H12(dia2)), 3.84-3.89 (m, 
2H, H2), 3.83 – 3.77 (m, 2H, H9), 3.76 – 3.64 (m, 2H, H12), 3.53 – 3.45 (m, 2H, H2(dia2)), 3.44-3.36 
(m, 1H, H12(dia2)), 3.09-3.02 (m, 2H, H8), 3.02 – 2.99 (m, 2H, H10), 2.98-2.92 (m, 2H, H8(dia2)), 1.89 
– 1.77 (m, 4H, H11), 1.77 – 1.65 (m, 4H, H3), 1.65 – 1.54 (m, 4H, H5), 1.55-1.45 (m, 4H, H4), 1.08 – 
1.04 (m, 42H, H15/H16). 
13
C NMR (126 MHz, CDCl3): δ 98.8 (C6), 98.5 (C6), 67.9 (C12), 66.8 (C12(dia2)), 62.0 (C2), 61.9 
(C2(dia2)), 60.2 (C9), 57.3 (C10(dia2)), 56.9 (C10), 53.8 (C8), 35.3 (C3), 30.5 (C5(dia2)), 30.4 (C5), 
25.4 (C4), 19.2 (C11(dia2)), 19.1 (C11), 18.0 (C16), 11.9 (C15). 
vmax (FTIR)cm
-1
: 2942 (C-H), 2865 (C-H), 1463, 1106 (C-O), 1032 (C-O). 
HRMS: calcd for C19H38O4SiNa, m/z = 381.2432, found 381.2433. 
[α]D
23
 = -29.2 (c = 2.00), CH2Cl2). 
 
Preparation of 4-azido-2,4-dideoxy-5-O-(tetrahydro-2H-pyran-2-yl)-1-O-
(triisopropylsilyl)-D-erythro-pentitol) (2.46) and 3-azido-3,4-dideoxy-1-O-(tetrahydro-2H-
pyran-2-yl)-5-O-(triisopropylsilyl)-D-erythro-pentitol (2.47) 
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These novel compunds were synthesised using a modification of the procedure according to 
Zwanenburg et al.
89
. 
To a stirring solution of (2.45) (3.00 g, 8.4 mmol) in MeOH/H2O (10:3, v/v) (39 mL) at rt was 
added sodium azide (1.09 g, 16.79 mmol) and (NH4)2SO4 (1.33 mg, 1.7 mmol) and mixture was 
heated to reflux. After 54 h the mixture was cooled, diluted with H2O (30 mL) and diethyl ether 
(50 mL). The organic components were extracted using diethyl ether  (2 x 50 mL) combined, 
washed with brine (1 x 50 mL) then dried (Na2SO4), concentrated under reduced pressure and 
purified via column chromatography on neutral silica eluting with hexanes/diethyl ether (9:1-
4:1) to afford an inseparable mixture of the title compounds (2.46) and (2.47) (2.62 g, 78 %) as 
a yellow oil. 
 
1
H NMR and 
13
C NMR values have been characterised by arbitrary assignment of peaks 
due to recognition of diastereomers caused by the chirality of THP group. Compounds 
confirmed by associated Mass and IR data.  
(2.46) 
1
H NMR (500 MHz, CDCl3): δ  δ 4.60-4.59 (m, 1H, H6(dia2)), 4.59-4.55 (m, 1H, H6), 3.95 – 3.91 (m, 
2H, H9(dia2)), 3.91 – 3.85 (m, 4H, H8), 3.85 – 3.82 (m, 2H, H2), 3.81 – 3.80 (m, 2H, H12(dia2)), 3.79 – 
3.73 (m, 2H, H10), 3.73-3.71 (m, 2H, H2(dia2)), 3.71 – 3.67 (m, 2H, H12), 3.59 – 3.51 (m, 1H, H9), 2.05 
– 1.96 (m, 1H, H11(dia2)), 1.96 – 1.87 (m, 1H, H11(dia2)), 1.87 –1.77 (m, 2H, H4), 1.77 – 1.63 (m, 4H, 
H5), 1.62 – 1.57 (m, 2H, H11), 1.57 - 1.55 (m, 4H, H3), 1.55 - 1.49 (m, 2H, H4(dia2)), 1.14 – 1.01 (m, 
42H, H16/H16)
 
13
C NMR (126 MHz, CDCl3): δ 100.42 (C6), 100.10 (C6(dia2)), 72.92 (C12(dia2)), 72.71 (C12), 70.15 
(C2(dia2)), 69.75 (C2) 63.34 (C9), 63.12 (C9(dia2)), 60.88 (C10(dia2)), 60.75 (C10), 59.73 (C8), 59.69 
(C8(dia2)), 33.54 (C11), 33.42 (C11(dia2)), 30.68 (C5), 25.18 (C3), 19.97 (C4), 19.78 (C4(dia2)), 17.97 
(C16), 11.94 (C15). 
vmax (FTIR)cm
-1
: 3407 (OH), 2942 (C-H), 2866 (C-H), 2100 (N3), 1463 (C-H), 1258 (Si-CH3), 1102 (C-
Oester), 1064, 1032,  881 (Si-C), 679 (Si-C). 
HRMS: calcd for C19H39O4SiNa, m/z = 424.2602, found 424.2609. 
[α]D
22
 = 11.5 (c = 1.40, CH2Cl2). 
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 (2.47) 
1
H NMR (500 MHz, CDCl3): δ  δ 4.69 – 4.64 (m, 2H, H6), 4.12 – 4.05 (m, 1H, H12), 4.05 – 3.99 (m, 2H, 
H8), 3.94-3.93 (m, 1H, H12), 3.92 – 3.89 (m, 2H, H8(dia2)), 3.89-3.84 (m, 4H, H2), 3.77-3.73 (m, 1H, 
H12), 3.61 – 3.57 (m, 1H, H12), 3.57 – 3.54 (m, 1H, H10(dia2)), 3.54 – 3.51 (m, 2H, H9), 3.51-3.49 (m, 
1H, H10), 1.91 – 1.79 (m, 4H, H11), 1.79 – 1.66 (m, 4H, H5), 1.67 – 1.56 (m, 4H, H3), 1.55 – 1.46 (m, 
4H, H4), 1.10 – 1.05 (m, 42H, H15/H16). 
13
C NMR (126 MHz, CDCl3): δ 99.4 (C6(dia2)), 98.5 (C6), 71.8 (C2(dia2)), 71.4 (C2), 67.7 (C12(dia2)), 
67.2 (C12) 65.5 (C10(dia2)), 65.3 (C10), 63.0 (C8(dia2)), 62.8 (C8), 62.1 (C9(dia2)), 61.8 (C9), 34.8 
(C11(dia2)), 34.6 (C11), 30.3 (C5), 25.4 (C3), 19.1 (C4(dia2)), 18.9 (C4), 17.9 (C16), 11.7 (C15). 
vmax (FTIR)cm
-1
: 3474 (OH), 2942 (C-H), 2866 (C-H), 2096 (N3), 1463 (C-H), 1262 (Si-CH3), 1122 (C-
Oester), 1065, 1032,  881 (Si-C), 679 (Si-C). 
HRMS: calcd for C19H39O4SiNa, m/z = 424.2602, found 424.2606. 
[α]D
24
 = -9.3 (c = 2.00, CH2Cl2). 
 
Preparation of ((2R,3S)-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-{2-
[(triisopropylsilyl)oxy]ethyl}aziridine (2.42) 
 
(2.42)
1
2
O
3
4
5
6
O
7
8
9
10
11
12
O
13
HN
14
Si(iPr)2
15
16
 
 
This novel compound was synthesised using a modification of the procedure according to 
Zwanenburg et al.
89
. 
To a stirring solution of (2.46) and (2.47) (9.00 g, 22.4 mmol) in MeCN (120 mL) at rt was 
added triphenylphosphine (6.17 g 23.5 mmol). After 10 mins the mixture was heated to reflux. 
Following 4 h the mixture was cooled, diluted with diethyl ether (100 mL) and placed in freezer 
overnight. The precipitate was filtered off and filtrate concentrated under reduced pressure 
before addition of hexanes (50 mL) and precipitate again filtered before concentrating under 
reduced pressure. The residue was subjected to column chromatography eluting with 
hexanes/diethyl ether (1:3) to afford the title compound (2.42) (7.70 g, 96 %) as yellow oil. 
 
1
H NMR and 
13
C NMR values have been characterised by arbitrary assignment of peaks 
due to recognition of diastereomers caused by the chirality of THP group. Compounds 
confirmed by associated Mass and IR data. 
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1
H NMR (500 MHz, CDCl3): δ 4.62 – 4.54 (m, 2H, H6), 3.84 – 3.80 (m, 2H, H8(dia2)), 3.78 (t, J = 6.1 
Hz, 4H H2), 3.60 (m, 2H, H8), 3.46 (app. t, J = 5.5 Hz, 2H, H12), 3.43 (app. t, J = 5.5 Hz, 2H, H12) 3.34 
(s, 2H, H17), 1.93 (m, 1H, H9), 1.82 – 1.73 (m, 2H, H11(dia2)), 1.71 – 1.66 (m, 1H, H10), 1.66 – 1.62 
(m, 4H, H5), 1.56-1.50 (m, 4H, H4), 1.50 – 1.47 (m, 4H, H3), 1.47 – 1.42 (m, 2H, H11(dia2)), 1.03- 1.00 
(m, 21H, H15/H16). 
13
C NMR (126 MHz, CDCl3): δ 98.8 (C6(dia2)), 98.4 (C6), 68.7 (C8(dia2)), 62.2 (C12), 61.9 (C8), 61.6 
(C2) 61.6 (C2(dia2)), 36.8 (C10), 36.0 (C9), 30.5 (C5), 30.4 (C4), 25.4 (C3), 19.4 (C11(dia 2), 19.2 
(C11), 17.9 (C15), 11.9 (C16). 
vmax (FTIR)cm
-1
: 3292 (N-H), (2942 (C-H), 2866 (C-H), 1463, 1200 (Si-CH3), 1119 (Si-OR), 882 (Si-C). 
HRMS: calcd for C19H40O3SiNa, m/z = 358.2772, found 358.2769. 
[α]D
24
 = 23.3 (c = 1.95 in CH2Cl2). 
 
Preparation of ethyl (2E)-3-[(2S)-1-tritylaziridin-2-yl]acrylate (2.52) 
 
(2.52)
N1
2
3 4
5
6
Ph
Ph
8 9
10
11 12
13
14
CO2CH2Me
 
 
This novel compound was synthesised using a modification of the procedure according to Fujii 
et al.
100
. 
To a stirring solution of methyl (S)-(-)-1-tritylaziridine-2-carboxylate (2.53) (1.0 g, 2.91 mmol) 
in CH2Cl2 (10 mL) at -78°C was added dropwise DIBAL-H (1M in diethyl ether) (3.2 mL, 3.20 
mmol). Following 1 h solution was warmed to -10°C and saturated aqueous NH4Cl (1.8 mL) 
was added followed by cannular addition of the sodium salt of triethyl phosphonoacetate (1.96 g 
8.74 mmol) in THF (15 m L). Following 16 h at rt, liquid decanted off solid and solvent 
removed under reduced pressure. The residue was subject to column chromatography eluting 
with diethyl ether/hexanes (5:95) to afford the title compound (2.52) (965 mg, 86 %) as a white 
solid. 
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1
H NMR (500 MHz, CDCl3): δ 7.53-7.18 (m 15H, H12/H13/H14(aromatics)) 6.95 (dd, J = 8.1, 15.57 1H, 
H4), 6.04 (d, J = 15.57 Hz, 1H, H5), 4.22 (q, J = 14.33, 7.2 Hz, 2H, H8), 1.92 (app. d, J = 2.45 Hz, 1H, 
H2), 1.83 (t, J = 6.83 Hz, 1H, H3), 1.50 (app. d, J = 6.83 Hz, 1H, H2), 1.31 (t, J = 7.1 Hz, 3H, H9).
 
13
C NMR (126 MHz, CDCl3): δ 166.3 (C10), 149.9 (C4), 144.0 (C6), 129.4 (C12), 127.5 (C13), 126.8 
(C14), 122.0 (C5), 74.5 (C11), 60.3 (C8), 33.1 (C2), 30.7 (C3), 14.2 (C9). 
vmax (FTIR)cm
-1
: 3057 (C-H), 2982 (C-H), 2866 (C-H), 1714 (C=O). 
HRMS: calcd for C26H25NO2Na, m/z = 406.1778, found 406.1773. 
[α]D
22
 = -138.9 (c = 1.20, CHCl3). 
Mp. 38.5-41.1°C. 
 
Preparation of ethyl (2E)-3-[(5S)-2-oxo-3-trityl-1,3-oxazolidin-5-yl]acrylate (2.56) 
 
(2.56)
N
1
2
O
3
4
5
6
7
CO2CH2Me
8O 10
Ph
11
12
Ph 13 14
15
16
 
 
This novel compound was synthesised using a modification of the procedure according to 
Pinhas et al.
101
. 
Aziridine (2.52) (387 mg, 1.01 mmol) was dissolved in stirring THF (15 mL) in a thick walled 
screw capped vial (30 mL). NaI (151 mg, 1.01 mmol) was added and the whole cooled to -78°C. 
Solid CO2 (8.0 g, 450 mmol) was added, the cap sealed and the vial placed behind a blast shield. 
After 2 days at rt the vial was again cooled to -78°C and the cap was carefully removed. The 
solution was washed with saturated aqueous sodium thiosulphate and organics extracted with 
diethyl ether (3 x 20 mL) combined, dried (Na2SO4) and filtered before concentrating under 
reduced pressure. The residue was subject to column chromatography eluting with 
hexanes/diethyl ether (3:2) to afford the title compound (2.56) (314 mg, 73 %) as gummy 
yellow solid (attempts at recrystallisation of highly insoluble material caused decomposition to 
black tar).  
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1
H NMR (500 MHz, CDCl3): δ 7.57-7.09 (m, 15H, H14/H15/H16(aromatics)) 6.85 (app. d, J = 15.3, Hz, 1H, 
H6), 6.12 (d, J = 15.6 Hz, 1H, H7), 4.34 (app. s br, 1H, H4), 4.27 – 4.12 (m, 2H, H10), 2.45 (dd, J = 8.0, 
3.73 Hz, 1H, H5), 2.32 (dd, J = 8.0, 3.73 Hz, 1H, H5), 1.29 (app. d, J = 3.6 Hz, 3H, H11). 
13
C NMR (126 MHz, CDCl3): δ 166.3 (C8), 147.8 (C6), 145.5 (C2), 128.6 (C14), 128.0 (C15), 126.6 
(C16), 121.3 (C7), 108.4 (C13), 70.6 (C4), 60.5 (C10), 48.8 (C5), 14.2 (C11). 
vmax (FTIR)cm
-1
: 3057 (C-H), (2926 (C-H), 2854 (C-H), 1704 (C=O). 
LRMS (EI
+
): m/z = 324 (78%), 243 (100%), 165 (17%). 
[α]D
22
 = 0.4 (c = 1.00, CHCl3). 
Mp. 37.9- 39.2 °C. 
 
Preparation of D-serine methyl ester hydrochloride (2.62) 
 
HO
1
2
3
CO2Me
6
NH2.HCl
5
(2.62)  
This known compound was synthesised using a modification of the procedure according to 
nudelman et al.
102
. 
Acetyl chloride (50 g, 319 mmol) was added dropwise to stirring MeOH (350 mL) at -5 °C. D-
Serine (25 g, 238 mmol) was added in one portion and the mixture was heated to reflux. 
Following 3 h, the solvent was removed under vacuum and solid recrystallised from MeOH (45 
mL) to yield the title compound (2.62) (33.11 g, 89 %) as a white solid. 
1H NMR (500 MHz, DMSO) δ 8.64 (s, 3H, H1), 5.86 – 5.29 (brd. s , 1H, OH), 4.14 – 3.96 (m, 1H, H2), 
3.82 (d, J = 3.3 Hz, 2H, H6), 3.72 (s, 3H, H5). 
13C NMR (126 MHz, DMSO) δ 168.9 (C3), 59.9 (C6), 54.9 (C2), 53.2 (C5). 
vmax (FTIR)cm
-1
:  3343 (OH), 2918 (C-H), 1745 (C-0), 1038 (C-Oalcohol). 
HRMS: calcd for C4H10NO3Na, m/z = 120.0655, found 120.0658. 
[α]D
23
 = -4.1 (c = 1.05, MeOH). Lit. [α]D
20
 = -4.0
127 
Mp. 163-165°C. Lit. Mp = 164-166°C
127
.
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Preparation of methyl (4S)-2-oxo-1,3-oxazolidine-4-carboxylate (2.61) 
 
HN
1
2
O
3
4
5
O
CO2Me
6
(2.61)
8
 
 
This known compound was synthesised using a modification of the procedure according to 
Nudelman et al.
103
. 
Et3N (97.56 g, 964.1 mmol) was added to a stirring solution of (2.62) (50.0 g, 321.4 mmol) in 
CH2Cl2 (600 mL) at 0°C. Following 10 m a solution of triphosgene (47.68 g, 160.7 mmol) in 
CH2Cl2 (300 mL) was added dropwise over 2 h. Following 24 h at rt, the mixture was cooled to 
-78°C to precipitate any salts before filtering and removal of solvent under reduced pressure. 
The residue was purified on a plug of silica washed with AcOEt (300 mL) to provide title 
compound (2.61) (46.60 g, 100 %) as an orange oil. 
 
1
H NMR (500 MHz, CDCl3): δ 6.19 (s, 1H, H1), 4.61 (app. t, J = 9.2 Hz, 1H, H4), 4.53 (dd, J = 9.0, 4.6 
Hz, 1H, H4), 4.43 (dd, J = 9.2, 4.6 Hz, 1H, H5), 3.82 (s, 3H, H8). 
13
C NMR (126 MHz, CDCl3): δ 170.4 (C2), 158.8 (C6), 66.7 (C4), 53.71 (C5), 53.1 (C8). 
vmax (FTIR)cm
-1
:  3296 (OH) 2959 (C-H), 1727 (C=O), 1209. 
HRMS: calcd for C5H7NO4Na, m/z = 168.0267, found 168.0268. 
[α]D
22
 = -18.2 (c = 1.05, CH2Cl2). Lit. [α]D
25 
= -18.6
128
. 
 
Preparation of methyl (4S)-3-(3-methylbut-2-en-1-yl)-2-oxo-1,3-oxazolidine-4-carboxylate 
(2.60) 
 
N
1
2
O
3
4
5
O
CO2Me
(2.60)
8
9
10
Me 11
Me
12
13
6
 
 
This novel compound was synthesised using a modification of the procedure according to 
Nudelman et al.
104
. 
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Oxazolidinone (2.61) (360 mg, 2.48 mmol) was added dropwise to a stirring suspension of NaH 
(65 mg 2.73 mmol) in 4:1 THF/DMF (5 mL). Upon complete dissolution of solids, 3,3-dimethyl 
allyl bromide (506 mg 3.23 mmol) was added dropwise. Following 16 h, water (5 mL) was 
added and organics extracted with diethyl ether (3 x 30 mL), combined, dried (Na2SO4) and 
solvent removed under reduced pressure. The residue was subject to column chromatography 
eluting with hexanes/ethyl acetate (3:1) to afford the title compound (2.60) (410 mg, 78 %) as a 
colourless liquid. 
1
H NMR (500 MHz, CDCl3): δ 5.13 (t, J = 7.4 Hz, 1H, H10), 4.50 – 4.36 (m, 1H, H4), 4.35 – 4.25 (m, 
2H, H4), 4.13 (dd, J = 14.8, 6.2 Hz, 1H, H9), 3.3 (dd, J = 14.8, 8.8 Hz, 1H, H9), 3.78 (s, 3H, H8), 1.76 (s, 
3H, H12), 1.65 (s, 3H, H13). 
13
C NMR (126 MHz, CDCl3): δ 170.3 (C6), 157.4 (C2), 139.0 (C11), 117.3 (C10), 64.3 (C4), 56.2 (C5),  
52.8 (C8), 40.9 (C9), 25.7 (C12), 17.7 (C13). 
vmax (FTIR)cm
-1
:  2919 (C-H), 1739 (C=O), 1207 (C-O), 1173. 
HRMS: calcd for C10H15NO4Na, m/z = 236.0893, found 236.0893. 
[α]D
24
 = +21.1 (c = 1.00, CH2Cl2). 
 
Preparation of ethyl (2E)-3-[(4R)-3-(3-methylbut-2-en-1-yl)-2-oxo-1,3-oxazolidin-4-
yl]acrylate (2.1) 
N
1
2
O
3
4
5
O
6
7
8
(2.1)
10 11
Me
12
Me
13
CO2CH2Me14
15
16
 
 
This novel compound was synthesised using a modification of the procedure according to 
Nudelman et al.
104
. 
To a stirring solution of methyl ester (2.60) (321 mg, 1.51 mmol) in CH2Cl2 (5 mL) at -78°C 
was added dropwise DIBAL-H(1M in diethyl ether) (2.4 mL, 2.4 mmol). Following 1 h solution 
was warmed to -10°C and sat. NH4Cl(aq) (3.0 mL) was added followed by cannular addition of 
ethyl (triphenylphosphoranylidene)acetate (1.57 g 4.52 mmol) in CH2Cl2 (5 mL) Following 16 h 
at rt, liquid was decanted off solid and solvent removed under reduced pressure. The residue 
was subject to column chromatography eluting with hexanes/ethyl acetate (4:1) to afford the 
title compound (2.1) (318 mg, 83 %) as a colourless liquid. 
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1
H NMR (500 MHz, CDCl3): δ 6.76 (dd, J = 8.5, 15.7 Hz,1H, H6), 6.00 (d, J = 15.6 Hz, 1H, H7), 5.13 ( t, 
J = 7.3 Hz, 1H, H13), 4.43 (app. t, J = 8.3 Hz, 1H, H4), 4.34 (app. dd, J = 15.3, 8.4 Hz, 1H, H5), 4.23 (q, 
J = 7.1 Hz, 2H, H10), 4.03 (dd, J = 15.0, 6.2 Hz, 1H, H12), 3.99 (dd, J = 8.4, 6.2 Hz, 1H, H4), 3.60 (dd, J 
= 15.1, 8.4 Hz, 1H, H12), 1.73 (s, 3H, H15), 1.63 (s, 3H, H16), 1.31 (t, J =  7.2 Hz, 3H, H11). 
13
C NMR (126 MHz, CDCl3): δ 165.0 (C8), 157.6 (C2), 143.0 (C7), 138.1 (C14), 125.7 (C6), 117.7 
(C13), 66.2 (C4), 61.0 (C10), 56.3 (C5), 40.3 (C12), 25.7 (C15), 18.0 (C16), 14.1 (C11). 
vmax (FTIR)cm
-1
:  2979 (C-H), 2911 (C-H), 1748 (C=O), 1717 (C=O), 1263, 1175 (C-O), 1055. 
HRMS: calcd for C13H19NO4Na, m/z = 276.1206, found 276.1215. 
[α]D
24
 = +36.7 (c = 1.10, CH2Cl2). 
 
Preparation of ethyl [(6S,7S)-6-isopropenyl-3-oxotetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-
7-yl]acetate (2.65) and ethyl [(6R,7S)-6-isopropenyl-3-oxotetrahydro-1H-pyrrolo[1,2-
c][1,3]oxazol-7-yl]acetate (2.69) 
 
(2.65)
N
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Ene precursor (2.1) (1 g 3.95 mmol) was dissolved in N,N-diethylaniline (20 mL) in a thick 
walled microwave vial (35 mL). The vial was placed in the microwave at 200 °C for 4 h. The 
crude solution was subject to column chromatography eluting with hexanes/ethyl acetate (5:1) 
to afford a semi-separable 7:1 mixture of novel compounds (2.65) and (2.69) (800 mg, 80 %) as 
a brown liquid. 
 
(2.65) 
1
H NMR (500 MHz, CDCl3): δ 4.94 (app. t, J = 1.6 Hz, 1H, H15), 4.75 (app. s, 1H, H15), 4.54 (dd, J = 
9.3, 8.3 Hz, 1H, H8), 4.22 (dd,  J = 9.3, 4.8 Hz, 1H, H8), 4.17 – 4.06 (m, 2H, H12), 3.86- 3.77 (m, 2H, 
H5/H4), 3.16 (dd, J = 11.8, 6.5 Hz, 1H, H4), 2.99 (app. dd, J = 14.4, 7.7 Hz, 1H, H7), 2.48 – 2.34 (m, 2H, 
H6/H9), 2.26 – 2.16 (m, 1H, H9), 1.73 (s, 3H, H16), 1.29 – 1.20 (t, J = 7.2 Hz,  3H, H13). 
 
13
C NMR (126 MHz, CDCl3): δ 172.2 (C10), 161.3 (C2), 142.3 (C14), 114.6 (C15), 68.8 (C8), 63.6 (C5), 
60.8 (C12), 49.7 (C4), 49.3 (C7), 43.1 (C6), 33.3 (C9), 22.5 (C16), 14.1 (C13). 
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vmax (FTIR)cm
-1
:  2980 (C-H), 2913 (C-H), 1748 (C=O), 1726 (C=O), 1263, 1175 (C-O). 
HRMS: calcd for C13H19NO4Na, m/z = 276.1206, found 276.1217. 
[α]D
23
 = -14.4 (c = 1.01, CH2Cl2). 
 
(2.69) 
1
H NMR (500 MHz, CDCl3): δ 4.89 (app. t, J = 1.5 Hz, 1H, H15), 4.86 (app. s, 1H, H15), 4.52 (dd, J = 
9.3, 8.3 Hz, 1H, H4), 4.42 (dd, J = 9.3, 4.2 Hz, 1H, H4), 4.16-4.09 (m, 2H, H12), 3.82 – 3.73 (m, 1H, 
H5), 3.47 (app. t, J = 10.7 Hz, 1H, H8), 3.40 (app. t, J = 10.2 Hz, 1H, H8), 2.78 – 2.67 (m, 1H, H7), 2.57  
(dd, J =  3.6, 15.7 Hz, 1H, H9), 2.19 (dd, J = 9.7, 15.3 Hz, 1H, H9), 2.15 – 2.07 (m, 1H, H6), 1.71 (s, 3H, 
H16), 1.27 (t, J = 7.1 Hz, 3H, H13). 
 
13
C NMR (126 MHz, CDCl3): δ 172.0 (C10), 161.4 (C2), 141.3 (C14), 114.7 (C15), 67.8 (C4), 64.7 (C5), 
60.9 (C12), 55.0 (C7), 48.67 (C8), 43.3 (C6), 35.3 (C9), 18.1 (C16), 14.1 (C13). 
vmax (FTIR)cm
-1
:  2974 (C-H), 2904 (C-H), 1750 (C=O), 17129 (C=O), 1206, 1175 (C-O). 
HRMS: calcd for C13H19NO4Na, m/z = 276.1206, found 276.1218. 
 
Preparation of methyl (2S,3S,4S)-2-(hydroxymethyl)-4-isopropenyl-3-(2-methoxy-2-
oxoethyl)pyrrolidine-1-carboxylate (2.64) 
 
1
2
N
34
5
6 8
CO2Me
9
10
11
CO2Me
OH
1314
15
16
(2.64)  
 
This known compound was synthesised using a modification of the procedure according to Kern 
et al.
122
. 
To a stirring solution of ene-product (2.65) (500 mg, 1.97 mmol) in MeOH (4 mL) at rt was 
added in one portion Cs2CO3 (32 mg, 0.1 mmol). Following 6 d reaction was quenched with 
H2O (5 mL) and extracted with AcOEt (3 x 15 mL). Organics combined, dried (Na2SO4) and 
solvent removed under reduced pressure. The residue was subject to column chromatography 
eluting with hexanes/ethyl acetate (3:2) to afford the title compound (2.64) (426 mg, 80 %) as a 
brown oil. 
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1
H NMR (500 MHz, CDCl3): δ 4.89 (app. s, 1H, H15), 4.64 (app. s, 1H, H15), 3.76 (app. s, 1H, H2), 3.70 
(app. s, 5H, H5/H8), 3.65 (s, 3H, H13), 3.47-3.41 (m, 2H, H9), 3.00-2.92 (m, 1H, H4), 2.56 (app. s, br, 
1H, H3), 2.29-2.16 (m, 2H, H10), 1.69 (s, 3H, H6). 
13
C NMR (126 MHz, CDCl3): δ 172.7 (C11), 157.3 (C6), 141.6 (C14), 112.9 (C15), 65.8 (C5), 65.4 (C2), 
52.8 (C8), 51.7 (C13), 48.3 (C9), 45.6 (C4), 39.0 (C3), 33.0 (C10), 22.3 (C16). 
vmax (FTIR)cm
-1
:  3454 (O-H), 2920 (C-H), 2850 (C-H), 1735 (C=O), 1678 (C=O), 1450, 1376. 
HRMS: calcd for C13H22NO5, m/z = 272.11492, found 272.1499. 
[α]D
23
 = -42.3 (c = 1.00, CH3Cl). Lit. [α]D
20
 = -41.2
55
. 
Rf = 0.26 (1:1 AcOEt : Petrol). 
 
Preparation of methyl (2S,3S,4S)-2-formyl-4-isopropenyl-3-(2-methoxy-2-
oxoethyl)pyrrolidine-1-carboxylate (2.63) 
 
1
2
N
34
5
6 8
CO2Me
9
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11
CO2Me
O
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16
(2.63)  
 
This novel compound was synthesised using a modification of the procedure according to 
Parikh et al.
123
. 
Py.SO3 (3.78 g, 23.7 mmol) was dissolved in DMSO (8.3 mL) and CH2Cl2 (11 mL) and cooled 
to 0°C. Et3N (4.1 mL, 29.7 mmol) was added dropwise. After 10 min alcohol (2.64) (1.61 g 5.93 
mmol) in CH2Cl2 (11 mL) was added dropwise at 0°C. Mixture was allowed to warm to rt. 
Following 16 h sat. NH4Cl(aq) (20 mL) was added and extracted with CH2Cl2 (3 x 15 mL). 
Organics combined, dried (Na2SO4) and solvent removed under reduced pressure. The residue 
was subject to column chromatography eluting with petrol/ethyl acetate (3:1) to afford the title 
compound (2.63) (1.42 g, 89 %) as a yellow oil. 
 
1
H NMR (500 MHz, CDCl3): δ 9.58 (s, 0.5H, H9rot), 9.55 (s, 0.5H, H9rot), 4.90 (app. s, 1H, H15), 4.67 (d, 
J = 13.6 Hz, 1H, H15), 4.19 (d, J = 3.1 Hz, 0.5H, H2rot), 4.08 (d, J = 3.1 Hz, 0.5H, H2rot) 3.72 (app. s, 1H, 
H5), 3.70 – 3.60 (m, 6H, H8/H13), 3.55 (dd, J = 10.7, 8.5 Hz, 0.5H, H5rot), 3.46 (dd, J = 10.1, 8.7 Hz, 
0.5H, H5rot) 2.91-2.83 (m, 1H, H3), 2.84 – 2.72 (m, 1H, H4), 2.36 – 2.27 (m, 1H, H10), 2.27 – 2.12 (m, 
1H, H10), 1.68 (s, 3H, H16). 
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13
C NMR (126 MHz, CDCl3): δ 198.5 (C9), 172.3 (C11), 155.7 (C3), 140.9 (C14), 113.8 (C15), 69.8 
(C2), 51.9 (C8), 48.4 (C13), 47.9 (C5), 45.9 (C4), 38.5 (C3), 32.1 (C10), 22.3 (C16). 
vmax (FTIR)cm
-1
:  2958 (C-H), 1693 (C=O), 1689 (C=O), 1449, 1380, 1131 (C-O). 
HRMS: calcd for C13H19NO5Na, m/z = 292.1155, found 292.1156. 
[α]D
23
 = -58.1 (c = 1.05, CH2Cl2). 
Rf = 0.26 (1:3 AcOEt : Petrol). 
Preparation of (-)-α-Kainic Acid (1.1) 
3
2N
H
15
7
CO2H
6
9
10
11 CO2H
8
(-)--kainic acid (1.1)
4
 
 
(1) This natural product was synthesised using a modification of the procedures according to 
Pinnick et al.
125
 and Oppolzer et al.
17
. 
To a stirring solution of aldehyde (2.63) (1.42 g, 5.28 mmol) in 
t
BuOH (15 mL) and 2-methyl 2-
butene (25 mL) at rt was added dropwise a solution of sodium chlorite (4.30 g, 47.5 mmol) and 
sodium dihydrogenphosphate (5.76 g, 36.9 mmol) in water (150 mL) over a period of 10 m. 
After 16 h the volatiles were removed under reduced pressure and the residue was dissolved in 
water (25 mL) and extracted with hexanes (3 x 25 mL). Aqueous phase was acidified to pH 3 
with conc. HCl(aq) and extracted with diethyl ether (3 x 50 mL). Organics combined, dried 
(Na2SO4) and concentrated under reduced pressure to yield a crude acid which was used without 
further purification. 
(2) The crude acid was dissolved in stirring MeOH (70 mL) and NaOH(38%) (70 mL) was 
added. Mixture heated to reflux. Following 18 h solvent was removed under reduced pressure 
and crude product was added to a column containing Dowex-50 H
+
 (WX8-200 cross-linking, 
100-200 wet mesh). Elution with NH4OH (1M), evaporation and treatment with Amberlite CG-
50 (100-200 dry mesh) afforded after recrystallisation from water, the title compound (-)-α-
kainic acid (1.1) (720 mg, 60 %) as white needle crystals. 
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1
H NMR (500 MHz, D2O): δ 4.98 (app. s, 1H, H10), 4.69 (app. S, 1H, H10), 4.03 (s 1H, H2), 3.64 (dd, 
1H, J = 11.5, 8.5 Hz, H5), 3.35 (app. t, J = 11.5 Hz, 1H, H5), 3.06-2.99 (m, 1H, H4), 2.98-2.92 (m, 1H, 
H3), 2.44-2.36 (m, 1H, H7), 2.35-2.27 (m, 1H, H7), 1.70 (s, 3H, H11).  
13
C NMR (126 MHz, D2O): δ 176.2 (C8), 173.7 (C6), 139.9 (C9), 113.4 (C10), 65.6 (C2), 46.4 (C5), 45.7 
(C3), 40.7 (C4), 33.3 (C7), 22.1 (C11). 
vmax (FTIR)cm
-1
:  3534, 2976 (C-H), 2528 (C-H), 1689 (C=O), 1615 (C=O), 1383, 1276, 891. 
HRMS: calcd for C10H16NO4Na, m/z = 214.1074, found 214.1077. 
[α]D
23
 = -14.6 (c = 0.65, H2O). Lit. [α]D
20 
= -14.6
66
. 
Mp. 244.5-245°C. Lit Mp. 245°C
66
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1H-NMR Spectra for Moshers ester of (2.37) epoxidised with (+)DET 
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1H-NMR Spectra for Moshers ester of (2.37) epoxidised with (+)DIPT 
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Zoom view of dds around δ 4.64 (+)DET 
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Zoom view of dds around δ 4.64 (+)DIPT 
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Crystallographic Information for (-)-(α)-kainic acid (1.1) 
Table 1.  Crystal data and structure refinement for C10H15NO4·H2O (Kainic Acid – monohydrate) 
Identification code  jun511 
Empirical formula  C10 H17 N O5 
Formula weight  231.25 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21 (No.4) 
Unit cell dimensions a = 8.1222(4) Å = 90°. 
 b = 5.8322(3) Å = 94.629(2)°. 
 c = 11.9013(6) Å  = 90°. 
Volume 561.93(5) Å3 
Z 2 
Density (calculated) 1.37 Mg/m3 
Absorption coefficient 0.110 mm-1 
F(000) 248 
Crystal size 0.22 x 0.20 x 0.15 mm3 
Theta range for data collection 1.72 to 27.50°. 
Index ranges -10<=h<=10, -7<=k<=7, -15<=l<=15 
Reflections collected 7320 
Independent reflections 1400 [R(int) = 0.060] 
Completeness to theta = 27.50° 98.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1400 / 1 / 165 
Goodness-of-fit on F2 1.165 
Final R indices [I>2sigma(I)] R1 = 0.041, wR2 = 0.122 
R indices (all data) R1 = 0.052, wR2 = 0.139 
Largest diff. peak and hole 0.48 and -0.29 e.Å-3 
 
Hydrogen atoms on CO2H, NH2 and water located on a difference map and refined; all others in 
calculated positions. Extensive hydrogen-bonding present in the crystal structure 
Absolute stereochemistry not determined 
Data collection KappaCCD , Program package WinGX , Abs correction not applied  
Refinement using SHELXL-97 , Drawing using ORTEP-3 for Windows  
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for jun511.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(1) -1988(2) 2349(4) 6594(2) 31(1) 
O(2) -411(3) 4139(4) 5421(2) 27(1) 
O(3) 3102(3) 8914(4) 5927(2) 24(1) 
O(4) 5568(2) 7193(4) 6029(2) 28(1) 
O(5) 8482(4) 7722(6) 7479(2) 39(1) 
N 4467(3) 3082(5) 6504(2) 18(1) 
C(1) 4621(3) 2847(6) 7776(2) 23(1) 
C(2) 3455(3) 4682(5) 8185(2) 20(1) 
C(3) 2103(3) 4895(5) 7193(2) 18(1) 
C(4) 3181(3) 4860(5) 6184(2) 17(1) 
C(5) 2821(4) 4264(6) 9330(2) 24(1) 
C(6) 3272(4) 2497(7) 9977(3) 33(1) 
C(7) 1675(5) 6088(7) 9702(3) 37(1) 
C(8) 851(3) 2917(5) 7193(2) 21(1) 
C(9) -656(3) 3143(5) 6382(2) 21(1) 
C(10) 4043(3) 7175(5) 6036(2) 18(1) 
 
Table 3.   Bond lengths [Å] and angles [°] for jun511. 
_____________________________________________________ 
O(1)-C(9)  1.222(3) 
O(2)-C(9)  1.312(4) 
O(3)-C(10)  1.270(4) 
O(4)-C(10)  1.240(3) 
N-C(4)  1.499(4) 
N-C(1)  1.516(4) 
C(1)-C(2)  1.534(4) 
C(2)-C(5)  1.515(4) 
C(2)-C(3)  1.551(4) 
C(3)-C(8)  1.538(4) 
C(3)-C(4)  1.542(3) 
C(4)-C(10)  1.538(4) 
C(5)-C(6)  1.320(5) 
C(5)-C(7)  1.503(5) 
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C(8)-C(9)  1.502(4) 
 
C(4)-N-C(1) 108.4(2) 
N-C(1)-C(2) 104.5(2) 
C(5)-C(2)-C(1) 115.9(3) 
C(5)-C(2)-C(3) 115.2(2) 
C(1)-C(2)-C(3) 103.4(2) 
C(8)-C(3)-C(4) 114.0(2) 
C(8)-C(3)-C(2) 111.6(2) 
C(4)-C(3)-C(2) 100.4(2) 
N-C(4)-C(10) 108.8(2) 
N-C(4)-C(3) 103.9(2) 
C(10)-C(4)-C(3) 111.7(2) 
C(6)-C(5)-C(7) 122.0(3) 
C(6)-C(5)-C(2) 123.4(3) 
C(7)-C(5)-C(2) 114.5(3) 
C(9)-C(8)-C(3) 116.1(2) 
O(1)-C(9)-O(2) 123.2(3) 
O(1)-C(9)-C(8) 121.6(3) 
O(2)-C(9)-C(8) 115.2(2) 
O(4)-C(10)-O(3) 125.9(3) 
O(4)-C(10)-C(4) 118.2(3) 
O(3)-C(10)-C(4) 115.9(2) 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
  
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
  
 O2-H2X         0.835    1.805   160.81    2.608    O3 [ -x, y-1/2, -z+1 ] 
  
 O5-H5Y         0.809    2.057   160.44    2.831    O4 
  
 O5-H5X         0.864    2.084   160.14    2.911    O1 [ x+1, y+1, z ] 
  
 N -H2N         0.887    1.859   169.52    2.736    O3 [ x, y-1, z ] 
  
 N -H1N         0.810    2.221   112.16    2.636    O4 
 N -H1N         0.810    2.229   141.09    2.904    O1 [ x+1, y, z ]
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